| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Helicobacter Infections | 504 | 2025 | 1264 | 57.940 |
Why?
|
| Helicobacter pylori | 533 | 2024 | 1321 | 55.990 |
Why?
|
| Stomach Neoplasms | 131 | 2025 | 540 | 19.380 |
Why?
|
| Proton Pump Inhibitors | 90 | 2025 | 261 | 18.200 |
Why?
|
| Anti-Bacterial Agents | 169 | 2024 | 2425 | 16.590 |
Why?
|
| Gastritis | 121 | 2024 | 371 | 12.840 |
Why?
|
| Gastric Mucosa | 144 | 2024 | 485 | 11.110 |
Why?
|
| Amoxicillin | 64 | 2024 | 121 | 9.920 |
Why?
|
| Clarithromycin | 66 | 2023 | 125 | 8.760 |
Why?
|
| Drug Therapy, Combination | 130 | 2024 | 1163 | 8.190 |
Why?
|
| Bismuth | 50 | 2023 | 79 | 7.850 |
Why?
|
| Drug Resistance, Bacterial | 57 | 2024 | 364 | 7.270 |
Why?
|
| Peptic Ulcer | 68 | 2020 | 148 | 7.050 |
Why?
|
| Anti-Ulcer Agents | 45 | 2018 | 111 | 6.210 |
Why?
|
| Metronidazole | 60 | 2023 | 155 | 5.770 |
Why?
|
| Omeprazole | 42 | 2021 | 98 | 5.370 |
Why?
|
| Gastritis, Atrophic | 20 | 2024 | 60 | 5.230 |
Why?
|
| Duodenal Ulcer | 63 | 2016 | 127 | 5.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 44 | 2018 | 307 | 4.920 |
Why?
|
| Humans | 872 | 2025 | 124793 | 4.860 |
Why?
|
| Precancerous Conditions | 28 | 2022 | 284 | 4.520 |
Why?
|
| Antigens, Bacterial | 59 | 2018 | 314 | 4.220 |
Why?
|
| Antacids | 19 | 2021 | 26 | 4.060 |
Why?
|
| Gastrointestinal Hemorrhage | 41 | 2021 | 225 | 3.720 |
Why?
|
| Anti-Infective Agents | 13 | 2023 | 265 | 3.650 |
Why?
|
| Breath Tests | 53 | 2023 | 179 | 3.640 |
Why?
|
| Barrett Esophagus | 25 | 2021 | 339 | 3.440 |
Why?
|
| Stomach Ulcer | 43 | 2014 | 92 | 3.410 |
Why?
|
| Bacterial Proteins | 65 | 2018 | 887 | 3.380 |
Why?
|
| Gastroesophageal Reflux | 27 | 2022 | 294 | 3.320 |
Why?
|
| Middle Aged | 331 | 2025 | 26716 | 3.150 |
Why?
|
| Sulfonamides | 11 | 2024 | 263 | 3.070 |
Why?
|
| Urea | 35 | 2023 | 227 | 2.930 |
Why?
|
| Pyrroles | 7 | 2024 | 179 | 2.860 |
Why?
|
| Gastrointestinal Diseases | 20 | 2018 | 332 | 2.790 |
Why?
|
| Tetracycline | 30 | 2021 | 77 | 2.750 |
Why?
|
| Male | 422 | 2025 | 61283 | 2.720 |
Why?
|
| Adenocarcinoma | 23 | 2021 | 1000 | 2.700 |
Why?
|
| Adult | 322 | 2025 | 29471 | 2.680 |
Why?
|
| Aged | 232 | 2025 | 19691 | 2.610 |
Why?
|
| Stomach | 41 | 2019 | 272 | 2.560 |
Why?
|
| Treatment Outcome | 94 | 2024 | 12342 | 2.510 |
Why?
|
| Biopsy | 63 | 2024 | 1239 | 2.500 |
Why?
|
| Esophageal Neoplasms | 23 | 2021 | 361 | 2.480 |
Why?
|
| Female | 371 | 2025 | 66553 | 2.370 |
Why?
|
| Antimicrobial Stewardship | 6 | 2024 | 84 | 2.320 |
Why?
|
| Microbial Sensitivity Tests | 33 | 2022 | 790 | 2.310 |
Why?
|
| Esomeprazole | 10 | 2024 | 31 | 2.310 |
Why?
|
| Organometallic Compounds | 27 | 2024 | 107 | 2.310 |
Why?
|
| Norwalk virus | 19 | 2015 | 170 | 2.260 |
Why?
|
| Caliciviridae Infections | 16 | 2023 | 328 | 2.030 |
Why?
|
| Dyspepsia | 26 | 2022 | 101 | 2.010 |
Why?
|
| Gastroscopy | 36 | 2020 | 102 | 2.000 |
Why?
|
| Aspirin | 21 | 2018 | 226 | 1.950 |
Why?
|
| Gastroenteritis | 19 | 2023 | 348 | 1.930 |
Why?
|
| Endoscopy, Gastrointestinal | 22 | 2020 | 243 | 1.880 |
Why?
|
| Endoscopy, Digestive System | 16 | 2018 | 153 | 1.850 |
Why?
|
| Polymerase Chain Reaction | 49 | 2016 | 1587 | 1.840 |
Why?
|
| Gastrins | 14 | 2017 | 33 | 1.820 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 12 | 2020 | 18 | 1.800 |
Why?
|
| Colonic Polyps | 5 | 2022 | 81 | 1.800 |
Why?
|
| Bacterial Outer Membrane Proteins | 19 | 2014 | 107 | 1.790 |
Why?
|
| DNA, Bacterial | 33 | 2019 | 474 | 1.770 |
Why?
|
| Colonoscopy | 11 | 2022 | 240 | 1.760 |
Why?
|
| Metaplasia | 30 | 2022 | 214 | 1.750 |
Why?
|
| Urease | 19 | 2012 | 73 | 1.680 |
Why?
|
| Prevalence | 64 | 2023 | 2451 | 1.680 |
Why?
|
| Crohn Disease | 20 | 2017 | 283 | 1.580 |
Why?
|
| Antibodies, Bacterial | 35 | 2012 | 388 | 1.560 |
Why?
|
| Paratuberculosis | 13 | 2023 | 17 | 1.520 |
Why?
|
| Hydrogen-Ion Concentration | 25 | 2022 | 426 | 1.500 |
Why?
|
| Clinical Trials as Topic | 20 | 2017 | 1090 | 1.490 |
Why?
|
| Endoscopy | 24 | 2024 | 284 | 1.480 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 14 | 2012 | 27 | 1.470 |
Why?
|
| Pepsinogen A | 7 | 2020 | 17 | 1.450 |
Why?
|
| Aged, 80 and over | 79 | 2021 | 6521 | 1.440 |
Why?
|
| Salicylates | 19 | 2004 | 53 | 1.410 |
Why?
|
| Gastric Acid | 14 | 2018 | 50 | 1.410 |
Why?
|
| Colon | 12 | 2025 | 352 | 1.380 |
Why?
|
| Campylobacter Infections | 20 | 1990 | 34 | 1.380 |
Why?
|
| Intestinal Mucosa | 22 | 2025 | 775 | 1.380 |
Why?
|
| Exocrine Pancreatic Insufficiency | 6 | 2019 | 34 | 1.360 |
Why?
|
| Gastroenterology | 8 | 2020 | 191 | 1.350 |
Why?
|
| Furazolidone | 5 | 2017 | 8 | 1.350 |
Why?
|
| Risk Factors | 72 | 2025 | 10272 | 1.340 |
Why?
|
| Probiotics | 7 | 2019 | 208 | 1.330 |
Why?
|
| Virulence Factors | 15 | 2017 | 176 | 1.320 |
Why?
|
| Practice Guidelines as Topic | 11 | 2021 | 1265 | 1.300 |
Why?
|
| Drug Administration Schedule | 25 | 2020 | 731 | 1.300 |
Why?
|
| Stomach Diseases | 14 | 2012 | 56 | 1.290 |
Why?
|
| Genes, Bacterial | 24 | 2021 | 209 | 1.290 |
Why?
|
| Prospective Studies | 61 | 2023 | 6137 | 1.280 |
Why?
|
| Hemostasis, Endoscopic | 9 | 2021 | 16 | 1.270 |
Why?
|
| Enzyme Therapy | 2 | 2019 | 5 | 1.250 |
Why?
|
| Interleukin-8 | 17 | 2019 | 209 | 1.250 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2025 | 691 | 1.220 |
Why?
|
| Intestine, Small | 8 | 2015 | 312 | 1.200 |
Why?
|
| Arthritis | 11 | 2018 | 81 | 1.190 |
Why?
|
| Esophagoscopy | 19 | 2021 | 156 | 1.180 |
Why?
|
| Feces | 25 | 2024 | 718 | 1.170 |
Why?
|
| Endoscopic Mucosal Resection | 3 | 2019 | 74 | 1.160 |
Why?
|
| Peptic Ulcer Hemorrhage | 11 | 2020 | 21 | 1.160 |
Why?
|
| Naproxen | 13 | 2018 | 20 | 1.120 |
Why?
|
| Time Factors | 53 | 2023 | 6309 | 1.110 |
Why?
|
| Ulcer | 8 | 2020 | 48 | 1.090 |
Why?
|
| Levofloxacin | 7 | 2023 | 45 | 1.070 |
Why?
|
| Immunoglobulin G | 30 | 2018 | 776 | 1.060 |
Why?
|
| Enzyme Inhibitors | 11 | 2007 | 580 | 1.060 |
Why?
|
| Genotype | 30 | 2017 | 2557 | 1.050 |
Why?
|
| Drug Resistance, Microbial | 21 | 2022 | 193 | 1.040 |
Why?
|
| Esophagus | 21 | 2018 | 215 | 1.030 |
Why?
|
| Gastric Bypass | 2 | 2017 | 70 | 1.020 |
Why?
|
| Pilot Projects | 21 | 2024 | 1402 | 1.020 |
Why?
|
| Ranitidine | 15 | 2005 | 31 | 1.010 |
Why?
|
| Hernia, Hiatal | 8 | 2016 | 54 | 1.010 |
Why?
|
| Primary Prevention | 3 | 2018 | 168 | 1.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 34 | 2020 | 824 | 1.000 |
Why?
|
| Double-Blind Method | 36 | 2021 | 1636 | 1.000 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2018 | 618 | 0.990 |
Why?
|
| Japan | 17 | 2023 | 133 | 0.980 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 8 | 2018 | 61 | 0.970 |
Why?
|
| Risk Assessment | 22 | 2025 | 3435 | 0.960 |
Why?
|
| Adolescent | 97 | 2025 | 19329 | 0.960 |
Why?
|
| Pyloric Antrum | 21 | 2007 | 64 | 0.940 |
Why?
|
| Host-Pathogen Interactions | 6 | 2019 | 254 | 0.940 |
Why?
|
| Adenoma | 5 | 2016 | 135 | 0.930 |
Why?
|
| Cyclooxygenase Inhibitors | 9 | 2009 | 64 | 0.930 |
Why?
|
| Carcinoma | 6 | 2013 | 285 | 0.920 |
Why?
|
| Abdominal Pain | 6 | 2019 | 309 | 0.910 |
Why?
|
| Treatment Failure | 15 | 2023 | 342 | 0.910 |
Why?
|
| Colonic Neoplasms | 4 | 2016 | 249 | 0.900 |
Why?
|
| Capsule Endoscopy | 3 | 2010 | 20 | 0.900 |
Why?
|
| Consensus | 3 | 2018 | 634 | 0.890 |
Why?
|
| Paraffin Embedding | 5 | 2021 | 33 | 0.880 |
Why?
|
| Rifabutin | 2 | 2021 | 4 | 0.880 |
Why?
|
| Duodenum | 11 | 2020 | 98 | 0.860 |
Why?
|
| Young Adult | 41 | 2024 | 8987 | 0.850 |
Why?
|
| Periodicals as Topic | 2 | 2024 | 196 | 0.840 |
Why?
|
| Histamine H2 Antagonists | 8 | 2020 | 49 | 0.830 |
Why?
|
| United States | 48 | 2021 | 10885 | 0.830 |
Why?
|
| Ofloxacin | 3 | 2013 | 32 | 0.820 |
Why?
|
| Pepsinogens | 4 | 2010 | 7 | 0.800 |
Why?
|
| Rotavirus | 35 | 2015 | 496 | 0.790 |
Why?
|
| Communicable Diseases | 2 | 2023 | 160 | 0.780 |
Why?
|
| Esophageal Stenosis | 12 | 2004 | 44 | 0.780 |
Why?
|
| Gastrointestinal Agents | 3 | 2020 | 60 | 0.770 |
Why?
|
| Norovirus | 7 | 2023 | 316 | 0.770 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 359 | 0.760 |
Why?
|
| Campylobacter | 14 | 1996 | 25 | 0.760 |
Why?
|
| Alendronate | 6 | 2013 | 19 | 0.740 |
Why?
|
| Penicillins | 12 | 2001 | 154 | 0.740 |
Why?
|
| Tissue Fixation | 1 | 2021 | 38 | 0.740 |
Why?
|
| Ribotyping | 1 | 2021 | 50 | 0.730 |
Why?
|
| Pepsinogen C | 4 | 2006 | 10 | 0.720 |
Why?
|
| Follow-Up Studies | 33 | 2022 | 5153 | 0.720 |
Why?
|
| Ants | 1 | 2020 | 8 | 0.720 |
Why?
|
| Bacteriological Techniques | 7 | 2018 | 86 | 0.710 |
Why?
|
| Virulence | 22 | 2017 | 262 | 0.710 |
Why?
|
| Animals | 86 | 2025 | 34184 | 0.710 |
Why?
|
| Intestinal Polyps | 5 | 2015 | 29 | 0.700 |
Why?
|
| Carbon Isotopes | 16 | 2016 | 277 | 0.700 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2021 | 79 | 0.690 |
Why?
|
| Sensitivity and Specificity | 32 | 2014 | 2044 | 0.690 |
Why?
|
| Citric Acid | 5 | 2005 | 36 | 0.690 |
Why?
|
| Histamine | 1 | 2020 | 44 | 0.680 |
Why?
|
| Illusions | 1 | 2020 | 8 | 0.680 |
Why?
|
| Disease Eradication | 3 | 2020 | 32 | 0.680 |
Why?
|
| Ascorbic Acid | 4 | 2012 | 78 | 0.680 |
Why?
|
| Hemostatics | 4 | 2021 | 58 | 0.670 |
Why?
|
| Propofol | 1 | 2020 | 44 | 0.670 |
Why?
|
| Incidence | 16 | 2020 | 3144 | 0.660 |
Why?
|
| Intestinal Neoplasms | 2 | 2019 | 39 | 0.660 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2019 | 3 | 0.660 |
Why?
|
| Recurrence | 26 | 2021 | 1425 | 0.660 |
Why?
|
| Celecoxib | 10 | 2018 | 32 | 0.650 |
Why?
|
| Empyema | 1 | 2019 | 23 | 0.650 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 869 | 0.640 |
Why?
|
| Serologic Tests | 11 | 2020 | 118 | 0.640 |
Why?
|
| Antitrichomonal Agents | 5 | 2001 | 10 | 0.640 |
Why?
|
| Molecular Sequence Data | 37 | 2016 | 3881 | 0.640 |
Why?
|
| Fluoroquinolones | 5 | 2018 | 93 | 0.630 |
Why?
|
| Chemical and Drug Induced Liver Injury | 4 | 2016 | 108 | 0.630 |
Why?
|
| Antibodies, Viral | 17 | 2015 | 1151 | 0.630 |
Why?
|
| Bacterial Adhesion | 9 | 2017 | 108 | 0.630 |
Why?
|
| Coloring Agents | 5 | 2006 | 79 | 0.620 |
Why?
|
| Registries | 9 | 2021 | 1422 | 0.620 |
Why?
|
| Enzymes | 1 | 2019 | 52 | 0.620 |
Why?
|
| Bacterial Vaccines | 7 | 2024 | 100 | 0.620 |
Why?
|
| Ibuprofen | 7 | 2018 | 41 | 0.620 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 566 | 0.600 |
Why?
|
| Mass Screening | 5 | 2020 | 785 | 0.600 |
Why?
|
| Adhesins, Bacterial | 10 | 2016 | 75 | 0.600 |
Why?
|
| Lactobacillus delbrueckii | 1 | 2018 | 2 | 0.600 |
Why?
|
| Proton Pumps | 3 | 2018 | 11 | 0.600 |
Why?
|
| Virus Shedding | 6 | 2023 | 80 | 0.600 |
Why?
|
| Cytochrome P-450 CYP2C19 | 2 | 2015 | 19 | 0.590 |
Why?
|
| Neoplasms | 5 | 2017 | 2788 | 0.590 |
Why?
|
| Odds Ratio | 14 | 2022 | 1252 | 0.590 |
Why?
|
| Global Health | 5 | 2020 | 558 | 0.580 |
Why?
|
| Cathartics | 2 | 2017 | 27 | 0.580 |
Why?
|
| Rotavirus Infections | 14 | 2015 | 354 | 0.580 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 117 | 0.580 |
Why?
|
| RNA, Ribosomal, 23S | 7 | 2016 | 21 | 0.570 |
Why?
|
| Lactones | 3 | 2019 | 39 | 0.560 |
Why?
|
| Atrophy | 12 | 2022 | 235 | 0.560 |
Why?
|
| Italy | 10 | 2018 | 113 | 0.560 |
Why?
|
| Intestines | 13 | 2020 | 572 | 0.560 |
Why?
|
| Minerals | 4 | 2021 | 58 | 0.560 |
Why?
|
| Age Distribution | 12 | 2018 | 415 | 0.550 |
Why?
|
| Sulfones | 3 | 2019 | 70 | 0.550 |
Why?
|
| Diarrhea | 14 | 1996 | 316 | 0.530 |
Why?
|
| Postoperative Hemorrhage | 3 | 2022 | 86 | 0.530 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 7 | 2006 | 61 | 0.530 |
Why?
|
| Neutrophils | 11 | 2009 | 379 | 0.530 |
Why?
|
| Lymph Nodes | 1 | 2018 | 380 | 0.530 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 1108 | 0.530 |
Why?
|
| Base Sequence | 31 | 2011 | 3099 | 0.530 |
Why?
|
| Hepatocytes | 2 | 2008 | 229 | 0.520 |
Why?
|
| Osteoarthritis | 4 | 2018 | 86 | 0.520 |
Why?
|
| Gastrectomy | 3 | 2014 | 90 | 0.520 |
Why?
|
| Gastric Juice | 7 | 2005 | 13 | 0.520 |
Why?
|
| Evidence-Based Medicine | 5 | 2019 | 632 | 0.520 |
Why?
|
| Dose-Response Relationship, Drug | 18 | 2020 | 1691 | 0.510 |
Why?
|
| Tablets, Enteric-Coated | 3 | 2014 | 6 | 0.510 |
Why?
|
| Viral Vaccines | 8 | 2015 | 334 | 0.500 |
Why?
|
| Severity of Illness Index | 16 | 2020 | 2903 | 0.500 |
Why?
|
| Amiodarone | 1 | 2016 | 45 | 0.500 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2018 | 205 | 0.500 |
Why?
|
| Gastric Emptying | 5 | 2014 | 78 | 0.500 |
Why?
|
| Socioeconomic Factors | 20 | 2017 | 873 | 0.500 |
Why?
|
| History, 20th Century | 4 | 2024 | 384 | 0.500 |
Why?
|
| Retrospective Studies | 33 | 2024 | 16299 | 0.500 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2015 | 12 | 0.490 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 13 | 0.490 |
Why?
|
| Magnetics | 1 | 2015 | 41 | 0.490 |
Why?
|
| Esophagitis, Peptic | 8 | 2005 | 33 | 0.490 |
Why?
|
| Cardia | 5 | 2007 | 27 | 0.490 |
Why?
|
| Magnets | 1 | 2015 | 22 | 0.490 |
Why?
|
| Milk | 3 | 2020 | 119 | 0.490 |
Why?
|
| Standard of Care | 1 | 2016 | 130 | 0.490 |
Why?
|
| Population Dynamics | 2 | 2014 | 32 | 0.480 |
Why?
|
| Diet | 7 | 2025 | 1136 | 0.480 |
Why?
|
| Malaysia | 5 | 2013 | 13 | 0.470 |
Why?
|
| Pancreas, Exocrine | 1 | 2014 | 6 | 0.470 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2014 | 17 | 0.470 |
Why?
|
| False Negative Reactions | 10 | 2020 | 89 | 0.470 |
Why?
|
| Cost-Benefit Analysis | 8 | 2020 | 511 | 0.470 |
Why?
|
| Cross-Sectional Studies | 29 | 2025 | 3448 | 0.460 |
Why?
|
| Nitrofurantoin | 3 | 2001 | 9 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 265 | 0.460 |
Why?
|
| Dexlansoprazole | 1 | 2014 | 1 | 0.460 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 28 | 0.460 |
Why?
|
| Point-of-Care Systems | 4 | 2023 | 172 | 0.460 |
Why?
|
| Lansoprazole | 10 | 2015 | 22 | 0.460 |
Why?
|
| Virus Replication | 12 | 2020 | 611 | 0.450 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2016 | 222 | 0.450 |
Why?
|
| Deglutition Disorders | 7 | 2024 | 130 | 0.450 |
Why?
|
| Celiac Disease | 5 | 2003 | 68 | 0.450 |
Why?
|
| Mycobacterium avium | 4 | 2001 | 15 | 0.440 |
Why?
|
| Conscious Sedation | 1 | 2014 | 61 | 0.440 |
Why?
|
| Predictive Value of Tests | 18 | 2018 | 2142 | 0.440 |
Why?
|
| Risk | 8 | 2023 | 757 | 0.440 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 1690 | 0.440 |
Why?
|
| Case-Control Studies | 17 | 2018 | 3287 | 0.440 |
Why?
|
| Cattle Diseases | 3 | 2023 | 21 | 0.430 |
Why?
|
| Misoprostol | 8 | 2004 | 26 | 0.430 |
Why?
|
| Epithelial Cells | 15 | 2019 | 910 | 0.430 |
Why?
|
| Protective Factors | 3 | 2018 | 85 | 0.430 |
Why?
|
| Child | 62 | 2025 | 24453 | 0.420 |
Why?
|
| Asia | 8 | 2017 | 107 | 0.420 |
Why?
|
| Age Factors | 22 | 2014 | 2817 | 0.420 |
Why?
|
| Helicobacter | 4 | 2024 | 17 | 0.420 |
Why?
|
| Genome, Bacterial | 5 | 2017 | 186 | 0.420 |
Why?
|
| Hypnotics and Sedatives | 1 | 2014 | 135 | 0.420 |
Why?
|
| False Positive Reactions | 8 | 2015 | 144 | 0.420 |
Why?
|
| History, 21st Century | 3 | 2024 | 269 | 0.420 |
Why?
|
| Dilatation | 7 | 2004 | 66 | 0.410 |
Why?
|
| Etidronic Acid | 3 | 2013 | 9 | 0.410 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 154 | 0.410 |
Why?
|
| Microbial Viability | 2 | 2017 | 42 | 0.400 |
Why?
|
| Ascorbic Acid Deficiency | 1 | 2012 | 2 | 0.400 |
Why?
|
| India | 6 | 2013 | 219 | 0.400 |
Why?
|
| Public Policy | 1 | 2012 | 51 | 0.400 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2018 | 263 | 0.390 |
Why?
|
| Biomarkers | 12 | 2020 | 3063 | 0.390 |
Why?
|
| Culture Media | 10 | 2011 | 182 | 0.390 |
Why?
|
| Prognosis | 16 | 2018 | 4607 | 0.390 |
Why?
|
| Taiwan | 6 | 2023 | 31 | 0.390 |
Why?
|
| Mental Health Services | 2 | 2025 | 256 | 0.390 |
Why?
|
| Legislation, Drug | 1 | 2011 | 9 | 0.380 |
Why?
|
| Research | 4 | 2020 | 263 | 0.380 |
Why?
|
| Hyperplasia | 4 | 2022 | 209 | 0.380 |
Why?
|
| Bacteria | 6 | 2025 | 484 | 0.380 |
Why?
|
| Catheter Ablation | 4 | 2021 | 238 | 0.380 |
Why?
|
| Child, Preschool | 40 | 2014 | 14050 | 0.380 |
Why?
|
| Preservation, Biological | 1 | 2011 | 9 | 0.370 |
Why?
|
| Stem Cells | 4 | 2019 | 702 | 0.370 |
Why?
|
| Esophageal Mucosa | 3 | 2020 | 11 | 0.370 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2012 | 70 | 0.370 |
Why?
|
| Anti-Infective Agents, Urinary | 2 | 2001 | 8 | 0.370 |
Why?
|
| Drug Monitoring | 2 | 2020 | 170 | 0.360 |
Why?
|
| Inflammation | 9 | 2022 | 1428 | 0.360 |
Why?
|
| Population Groups | 1 | 2010 | 30 | 0.360 |
Why?
|
| Catheterization | 5 | 1998 | 236 | 0.360 |
Why?
|
| Gastrointestinal Tract | 2 | 2019 | 215 | 0.360 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2005 | 28 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 8 | 2014 | 1017 | 0.360 |
Why?
|
| Indians, North American | 3 | 2018 | 59 | 0.360 |
Why?
|
| Genomic Islands | 6 | 2017 | 29 | 0.360 |
Why?
|
| Cattle | 12 | 2023 | 566 | 0.350 |
Why?
|
| NADH, NADPH Oxidoreductases | 2 | 2000 | 12 | 0.350 |
Why?
|
| Administration, Oral | 13 | 2014 | 683 | 0.350 |
Why?
|
| Taeniasis | 1 | 2010 | 3 | 0.350 |
Why?
|
| Meta-Analysis as Topic | 3 | 2021 | 157 | 0.350 |
Why?
|
| Family | 5 | 2017 | 565 | 0.340 |
Why?
|
| Radiography, Abdominal | 1 | 2010 | 47 | 0.340 |
Why?
|
| Diterpenes | 1 | 2010 | 28 | 0.340 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 1228 | 0.340 |
Why?
|
| Proton-Translocating ATPases | 2 | 2007 | 17 | 0.340 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2010 | 40 | 0.330 |
Why?
|
| RNA, Ribosomal, 16S | 9 | 2025 | 369 | 0.330 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 40 | 0.330 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 44 | 0.330 |
Why?
|
| DNA Methylation | 3 | 2020 | 1004 | 0.330 |
Why?
|
| Immunotherapy | 2 | 2014 | 665 | 0.330 |
Why?
|
| Bile | 3 | 2016 | 46 | 0.330 |
Why?
|
| Heartburn | 4 | 2022 | 15 | 0.330 |
Why?
|
| Surgical Instruments | 2 | 2010 | 55 | 0.330 |
Why?
|
| Aftercare | 1 | 2010 | 148 | 0.330 |
Why?
|
| Granuloma | 2 | 2008 | 68 | 0.330 |
Why?
|
| Logistic Models | 11 | 2016 | 1810 | 0.330 |
Why?
|
| Nucleic Acid Hybridization | 12 | 2001 | 395 | 0.320 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 258 | 0.320 |
Why?
|
| Amino Acid Sequence | 17 | 2016 | 2704 | 0.320 |
Why?
|
| Colitis, Ulcerative | 7 | 2015 | 208 | 0.320 |
Why?
|
| Polyps | 3 | 2013 | 45 | 0.320 |
Why?
|
| Staining and Labeling | 6 | 1999 | 187 | 0.320 |
Why?
|
| Virus Cultivation | 4 | 2019 | 76 | 0.310 |
Why?
|
| Environmental Microbiology | 1 | 2009 | 16 | 0.310 |
Why?
|
| Cyclooxygenase 2 | 6 | 2018 | 159 | 0.310 |
Why?
|
| Smoking | 5 | 2016 | 1044 | 0.310 |
Why?
|
| Immunoglobulin A | 11 | 2015 | 208 | 0.310 |
Why?
|
| Disease Progression | 6 | 2019 | 2052 | 0.310 |
Why?
|
| Membrane Proteins | 6 | 2004 | 1527 | 0.310 |
Why?
|
| Yogurt | 2 | 2025 | 12 | 0.310 |
Why?
|
| Fasting | 3 | 2001 | 302 | 0.310 |
Why?
|
| Endocytosis | 2 | 2008 | 124 | 0.310 |
Why?
|
| RNA, Bacterial | 4 | 2012 | 54 | 0.310 |
Why?
|
| CpG Islands | 1 | 2010 | 323 | 0.310 |
Why?
|
| Developing Countries | 4 | 2017 | 269 | 0.310 |
Why?
|
| Diphosphonates | 2 | 2013 | 38 | 0.310 |
Why?
|
| Antigens, Viral | 11 | 2012 | 437 | 0.300 |
Why?
|
| Capsules | 4 | 2017 | 21 | 0.300 |
Why?
|
| RNA, Messenger | 17 | 2017 | 2825 | 0.300 |
Why?
|
| Equipment Design | 6 | 2019 | 600 | 0.300 |
Why?
|
| Biopsy, Needle | 6 | 2019 | 229 | 0.300 |
Why?
|
| Interleukins | 4 | 2005 | 120 | 0.300 |
Why?
|
| Korea | 11 | 2008 | 35 | 0.300 |
Why?
|
| Agar | 4 | 2011 | 16 | 0.300 |
Why?
|
| Peptidyl Transferases | 3 | 2003 | 6 | 0.300 |
Why?
|
| Hexosyltransferases | 3 | 2003 | 7 | 0.300 |
Why?
|
| DNA Primers | 9 | 2014 | 660 | 0.300 |
Why?
|
| Cell Line | 26 | 2017 | 2771 | 0.300 |
Why?
|
| Reagent Strips | 3 | 1997 | 11 | 0.290 |
Why?
|
| Evaluation Studies as Topic | 12 | 1999 | 256 | 0.290 |
Why?
|
| Colombia | 10 | 2016 | 48 | 0.290 |
Why?
|
| Tetracycline Resistance | 3 | 2005 | 7 | 0.290 |
Why?
|
| Cimetidine | 7 | 1990 | 14 | 0.280 |
Why?
|
| Dairy Products | 2 | 2025 | 44 | 0.280 |
Why?
|
| DNA | 8 | 2008 | 1600 | 0.280 |
Why?
|
| Health Care Costs | 3 | 2019 | 371 | 0.280 |
Why?
|
| Nitroreductases | 3 | 2001 | 7 | 0.280 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 136 | 0.280 |
Why?
|
| Thailand | 5 | 2023 | 37 | 0.280 |
Why?
|
| Escherichia coli | 8 | 2000 | 986 | 0.280 |
Why?
|
| Colony Count, Microbial | 9 | 2002 | 89 | 0.280 |
Why?
|
| Single-Blind Method | 6 | 2008 | 238 | 0.280 |
Why?
|
| Carbon Dioxide | 5 | 2000 | 274 | 0.270 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 5 | 2002 | 369 | 0.270 |
Why?
|
| Fimbriae Proteins | 5 | 1991 | 20 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 467 | 0.270 |
Why?
|
| Africa | 6 | 2017 | 132 | 0.270 |
Why?
|
| Temperature | 7 | 2012 | 305 | 0.270 |
Why?
|
| Saliva | 5 | 2015 | 112 | 0.270 |
Why?
|
| Gastric Acidity Determination | 7 | 2004 | 19 | 0.270 |
Why?
|
| Congo Red | 1 | 2006 | 7 | 0.270 |
Why?
|
| Muramoylpentapeptide Carboxypeptidase | 3 | 2003 | 5 | 0.270 |
Why?
|
| Microscopy, Electron | 12 | 2001 | 396 | 0.270 |
Why?
|
| Sarcoidosis | 4 | 2000 | 61 | 0.270 |
Why?
|
| Esophageal and Gastric Varices | 7 | 1989 | 64 | 0.270 |
Why?
|
| Mucins | 1 | 2006 | 74 | 0.260 |
Why?
|
| Interleukin-6 | 5 | 2011 | 421 | 0.260 |
Why?
|
| Cardiovascular Diseases | 5 | 2018 | 1943 | 0.260 |
Why?
|
| Blood Loss, Surgical | 2 | 2020 | 152 | 0.260 |
Why?
|
| Bile Acids and Salts | 5 | 2020 | 245 | 0.260 |
Why?
|
| Escherichia coli Infections | 5 | 1990 | 195 | 0.260 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 49 | 0.260 |
Why?
|
| Parietal Cells, Gastric | 2 | 2022 | 38 | 0.260 |
Why?
|
| Sialic Acids | 3 | 1999 | 20 | 0.260 |
Why?
|
| Intention to Treat Analysis | 5 | 2018 | 64 | 0.260 |
Why?
|
| Sheep | 4 | 2001 | 215 | 0.260 |
Why?
|
| Feeding Behavior | 1 | 2012 | 712 | 0.260 |
Why?
|
| Hot Temperature | 2 | 1996 | 136 | 0.260 |
Why?
|
| Intensive Care Units | 2 | 2020 | 485 | 0.250 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2005 | 8 | 0.250 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2021 | 121 | 0.250 |
Why?
|
| Lactose | 3 | 1999 | 54 | 0.250 |
Why?
|
| Seroepidemiologic Studies | 10 | 2012 | 121 | 0.250 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2005 | 40 | 0.250 |
Why?
|
| Chi-Square Distribution | 5 | 2015 | 585 | 0.250 |
Why?
|
| Medication Adherence | 3 | 2015 | 401 | 0.250 |
Why?
|
| Tumor Cells, Cultured | 5 | 2003 | 1066 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2013 | 662 | 0.250 |
Why?
|
| Malates | 1 | 2005 | 7 | 0.250 |
Why?
|
| Brassica | 1 | 2005 | 14 | 0.250 |
Why?
|
| Microsatellite Repeats | 4 | 2000 | 219 | 0.250 |
Why?
|
| Social Work | 1 | 2025 | 20 | 0.240 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 674 | 0.240 |
Why?
|
| Cross-Over Studies | 6 | 2013 | 312 | 0.240 |
Why?
|
| Texas | 13 | 2018 | 3590 | 0.240 |
Why?
|
| Acetazolamide | 1 | 2005 | 30 | 0.240 |
Why?
|
| NF-kappa B | 6 | 2018 | 457 | 0.240 |
Why?
|
| Iron | 2 | 2006 | 268 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2013 | 1180 | 0.240 |
Why?
|
| Bone Wires | 1 | 2024 | 7 | 0.240 |
Why?
|
| Placebos | 6 | 2015 | 240 | 0.240 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2005 | 24 | 0.240 |
Why?
|
| Finger Joint | 1 | 2024 | 11 | 0.240 |
Why?
|
| Yeasts | 1 | 2024 | 42 | 0.240 |
Why?
|
| Adolescent Health Services | 1 | 2024 | 36 | 0.240 |
Why?
|
| Nontherapeutic Human Experimentation | 1 | 2004 | 7 | 0.240 |
Why?
|
| Phenotype | 12 | 2017 | 4260 | 0.240 |
Why?
|
| Cohort Studies | 16 | 2022 | 4783 | 0.230 |
Why?
|
| Finger Injuries | 1 | 2024 | 20 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2010 | 519 | 0.230 |
Why?
|
| Citrates | 2 | 2001 | 22 | 0.230 |
Why?
|
| Disease Models, Animal | 10 | 2019 | 4357 | 0.230 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2011 | 133 | 0.230 |
Why?
|
| Microbiological Techniques | 3 | 2014 | 32 | 0.230 |
Why?
|
| Cytokines | 6 | 2007 | 1290 | 0.230 |
Why?
|
| Disclosure | 1 | 2005 | 154 | 0.230 |
Why?
|
| Emigration and Immigration | 4 | 2018 | 81 | 0.230 |
Why?
|
| Fracture Fixation, Internal | 1 | 2024 | 77 | 0.230 |
Why?
|
| Disease Susceptibility | 4 | 2017 | 298 | 0.230 |
Why?
|
| Mouth | 1 | 2024 | 61 | 0.230 |
Why?
|
| Recovery of Function | 1 | 2006 | 444 | 0.220 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2005 | 196 | 0.220 |
Why?
|
| Foreign-Body Migration | 2 | 2004 | 74 | 0.220 |
Why?
|
| Reproducibility of Results | 14 | 2019 | 2880 | 0.220 |
Why?
|
| Apoptosis | 3 | 2018 | 1791 | 0.220 |
Why?
|
| Child Health Services | 1 | 2024 | 87 | 0.220 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 84 | 0.220 |
Why?
|
| Carrier Proteins | 6 | 2015 | 1026 | 0.220 |
Why?
|
| Self-Help Devices | 1 | 2023 | 12 | 0.220 |
Why?
|
| Editorial Policies | 1 | 2024 | 53 | 0.220 |
Why?
|
| Esophagogastric Junction | 2 | 2021 | 28 | 0.220 |
Why?
|
| beta-Lactam Resistance | 2 | 2003 | 46 | 0.220 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 5 | 2004 | 87 | 0.220 |
Why?
|
| Enterococcus | 1 | 2003 | 31 | 0.220 |
Why?
|
| Specimen Handling | 6 | 2005 | 141 | 0.220 |
Why?
|
| Europe | 6 | 2022 | 354 | 0.220 |
Why?
|
| Manometry | 3 | 2021 | 48 | 0.210 |
Why?
|
| Americas | 5 | 2017 | 50 | 0.210 |
Why?
|
| Porphyrins | 2 | 1996 | 16 | 0.210 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 462 | 0.210 |
Why?
|
| Salvage Therapy | 3 | 2017 | 194 | 0.210 |
Why?
|
| Comprehension | 1 | 2023 | 75 | 0.210 |
Why?
|
| Interleukin-17 | 2 | 2017 | 119 | 0.210 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2014 | 133 | 0.210 |
Why?
|
| Foreign Bodies | 4 | 2007 | 104 | 0.210 |
Why?
|
| Pancreatin | 4 | 1997 | 5 | 0.210 |
Why?
|
| Research Design | 6 | 2011 | 690 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 8 | 2010 | 1341 | 0.210 |
Why?
|
| Isoenzymes | 5 | 2004 | 228 | 0.210 |
Why?
|
| Patient Compliance | 8 | 2013 | 475 | 0.210 |
Why?
|
| Pancreas | 3 | 2018 | 217 | 0.210 |
Why?
|
| Lymphoid Tissue | 4 | 2002 | 47 | 0.210 |
Why?
|
| Interleukin-1 | 5 | 2005 | 142 | 0.210 |
Why?
|
| Random Allocation | 14 | 1995 | 436 | 0.210 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 90 | 0.210 |
Why?
|
| Heat-Shock Proteins | 2 | 1995 | 195 | 0.210 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2003 | 76 | 0.210 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 3338 | 0.200 |
Why?
|
| Intussusception | 1 | 2003 | 46 | 0.200 |
Why?
|
| Reference Values | 7 | 2011 | 712 | 0.200 |
Why?
|
| Esophageal Diseases | 4 | 2003 | 35 | 0.200 |
Why?
|
| Duodenal Neoplasms | 4 | 2021 | 21 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 449 | 0.200 |
Why?
|
| China | 6 | 2024 | 245 | 0.200 |
Why?
|
| Digestive System | 1 | 2002 | 59 | 0.200 |
Why?
|
| Antibody Formation | 5 | 2012 | 264 | 0.200 |
Why?
|
| Rabbits | 11 | 2005 | 711 | 0.200 |
Why?
|
| Cloning, Molecular | 9 | 2000 | 892 | 0.200 |
Why?
|
| Iran | 2 | 2024 | 59 | 0.200 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 530 | 0.200 |
Why?
|
| Surveys and Questionnaires | 17 | 2015 | 3726 | 0.190 |
Why?
|
| Child Abuse | 1 | 2024 | 195 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 223 | 0.190 |
Why?
|
| Cerebrovascular Disorders | 1 | 2002 | 122 | 0.190 |
Why?
|
| Nitrites | 1 | 2002 | 46 | 0.190 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2023 | 150 | 0.190 |
Why?
|
| Publishing | 1 | 2023 | 109 | 0.190 |
Why?
|
| Eosinophils | 2 | 2020 | 121 | 0.190 |
Why?
|
| Tablets | 4 | 2005 | 28 | 0.190 |
Why?
|
| Fixatives | 1 | 2021 | 14 | 0.190 |
Why?
|
| Obesity | 6 | 2016 | 2278 | 0.190 |
Why?
|
| Vaccines, Synthetic | 3 | 2018 | 317 | 0.190 |
Why?
|
| Sodium Bicarbonate | 3 | 2004 | 52 | 0.190 |
Why?
|
| Infant | 18 | 2010 | 12482 | 0.190 |
Why?
|
| Formaldehyde | 1 | 2021 | 35 | 0.190 |
Why?
|
| Salts | 1 | 2021 | 9 | 0.190 |
Why?
|
| Keratins | 1 | 2001 | 55 | 0.180 |
Why?
|
| Rabeprazole | 4 | 2018 | 5 | 0.180 |
Why?
|
| Hemagglutinins | 3 | 1993 | 23 | 0.180 |
Why?
|
| Cross Reactions | 5 | 2014 | 193 | 0.180 |
Why?
|
| Esophageal Motility Disorders | 1 | 2021 | 13 | 0.180 |
Why?
|
| Chronic Disease | 13 | 2013 | 1192 | 0.180 |
Why?
|
| In Situ Hybridization | 6 | 2001 | 470 | 0.180 |
Why?
|
| Mexico | 4 | 2010 | 180 | 0.180 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2001 | 23 | 0.180 |
Why?
|
| Electrodes | 2 | 1991 | 99 | 0.180 |
Why?
|
| Mycobacterium | 4 | 1988 | 28 | 0.180 |
Why?
|
| Ferredoxins | 1 | 2000 | 4 | 0.180 |
Why?
|
| Histocytochemistry | 4 | 2011 | 99 | 0.180 |
Why?
|
| Cell Degranulation | 1 | 2020 | 29 | 0.180 |
Why?
|
| Deglutition | 1 | 2021 | 49 | 0.180 |
Why?
|
| 3' Untranslated Regions | 1 | 2001 | 165 | 0.180 |
Why?
|
| Cat Diseases | 2 | 1997 | 14 | 0.170 |
Why?
|
| Veterans | 6 | 2020 | 1757 | 0.170 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2020 | 1 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2000 | 115 | 0.170 |
Why?
|
| Argon Plasma Coagulation | 1 | 2020 | 4 | 0.170 |
Why?
|
| Remission Induction | 3 | 2021 | 301 | 0.170 |
Why?
|
| Tetracyclines | 3 | 2005 | 17 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2013 | 65 | 0.170 |
Why?
|
| Phagocytosis | 1 | 2001 | 170 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 243 | 0.170 |
Why?
|
| Recombinant Proteins | 7 | 2004 | 1393 | 0.170 |
Why?
|
| Duodenitis | 3 | 2015 | 14 | 0.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2010 | 81 | 0.170 |
Why?
|
| Molecular Biology | 1 | 2000 | 79 | 0.170 |
Why?
|
| Ceramides | 1 | 2020 | 38 | 0.170 |
Why?
|
| Cannula | 1 | 2020 | 28 | 0.170 |
Why?
|
| Virus Internalization | 1 | 2020 | 56 | 0.160 |
Why?
|
| DNA Fingerprinting | 5 | 2007 | 107 | 0.160 |
Why?
|
| Benzimidazoles | 3 | 2006 | 133 | 0.160 |
Why?
|
| Gentamicins | 3 | 2010 | 95 | 0.160 |
Why?
|
| Warfarin | 2 | 2013 | 119 | 0.160 |
Why?
|
| Russia | 3 | 2014 | 39 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 101 | 0.160 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 9 | 2000 | 315 | 0.160 |
Why?
|
| Adjuvants, Immunologic | 2 | 2014 | 381 | 0.160 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 101 | 0.160 |
Why?
|
| Anticoagulants | 3 | 2022 | 592 | 0.160 |
Why?
|
| Lymphocyte Activation | 3 | 2014 | 692 | 0.160 |
Why?
|
| Waist-Hip Ratio | 3 | 2014 | 56 | 0.160 |
Why?
|
| Catalase | 5 | 2008 | 50 | 0.160 |
Why?
|
| Tracheoesophageal Fistula | 2 | 1991 | 48 | 0.160 |
Why?
|
| Potassium Chloride | 2 | 1990 | 53 | 0.160 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 19 | 0.160 |
Why?
|
| Hemoglobins | 3 | 2010 | 303 | 0.160 |
Why?
|
| Phylogeny | 5 | 2016 | 696 | 0.160 |
Why?
|
| Sclerotherapy | 2 | 1996 | 40 | 0.150 |
Why?
|
| Point Mutation | 2 | 2014 | 348 | 0.150 |
Why?
|
| Mutation | 13 | 2019 | 5811 | 0.150 |
Why?
|
| Sclerosing Solutions | 2 | 1989 | 13 | 0.150 |
Why?
|
| Bacteroides | 1 | 2019 | 34 | 0.150 |
Why?
|
| Viral Proteins | 11 | 1988 | 348 | 0.150 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 344 | 0.150 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 1697 | 0.150 |
Why?
|
| Liver Function Tests | 3 | 1995 | 101 | 0.150 |
Why?
|
| ErbB Receptors | 2 | 2011 | 284 | 0.150 |
Why?
|
| Interleukin-18 | 2 | 2009 | 60 | 0.150 |
Why?
|
| Patient Selection | 2 | 2018 | 693 | 0.150 |
Why?
|
| Dental Plaque | 2 | 1995 | 5 | 0.150 |
Why?
|
| Image Enhancement | 1 | 2019 | 165 | 0.150 |
Why?
|
| Postprandial Period | 1 | 2018 | 77 | 0.150 |
Why?
|
| Colitis | 2 | 2019 | 154 | 0.150 |
Why?
|
| Hong Kong | 1 | 2018 | 13 | 0.150 |
Why?
|
| History, Ancient | 3 | 2014 | 54 | 0.150 |
Why?
|
| Alaska | 1 | 2018 | 5 | 0.150 |
Why?
|
| Transcription Factor AP-1 | 4 | 2007 | 106 | 0.150 |
Why?
|
| Lactoferrin | 1 | 1999 | 77 | 0.150 |
Why?
|
| Condiments | 2 | 1988 | 3 | 0.150 |
Why?
|
| Genomic Instability | 2 | 2017 | 229 | 0.150 |
Why?
|
| Hypoxia | 1 | 2020 | 247 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 98 | 0.150 |
Why?
|
| Ferritins | 2 | 2011 | 97 | 0.150 |
Why?
|
| Esophagoscopes | 2 | 2013 | 4 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2019 | 1495 | 0.150 |
Why?
|
| DNA, Recombinant | 2 | 1997 | 100 | 0.150 |
Why?
|
| Physicians, Family | 1 | 1998 | 37 | 0.150 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2018 | 45 | 0.150 |
Why?
|
| Diseases in Twins | 2 | 1998 | 94 | 0.150 |
Why?
|
| Achlorhydria | 4 | 1993 | 6 | 0.150 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 1997 | 10 | 0.150 |
Why?
|
| Cell Wall | 3 | 2003 | 34 | 0.140 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 44 | 0.140 |
Why?
|
| Models, Theoretical | 2 | 2015 | 359 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 611 | 0.140 |
Why?
|
| Autoimmune Diseases | 2 | 2015 | 251 | 0.140 |
Why?
|
| Intestinal Absorption | 4 | 2014 | 190 | 0.140 |
Why?
|
| Radiography | 8 | 2024 | 828 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2024 | 824 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 410 | 0.140 |
Why?
|
| Phosphates | 1 | 2017 | 115 | 0.140 |
Why?
|
| Republic of Korea | 2 | 2015 | 38 | 0.140 |
Why?
|
| Latin America | 1 | 2017 | 89 | 0.140 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2018 | 101 | 0.140 |
Why?
|
| Serotyping | 1 | 1997 | 178 | 0.140 |
Why?
|
| Pancreatitis | 2 | 2018 | 130 | 0.140 |
Why?
|
| Sucrose | 1 | 1997 | 39 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2018 | 2609 | 0.140 |
Why?
|
| RNA, Viral | 9 | 2008 | 541 | 0.140 |
Why?
|
| Clinical Enzyme Tests | 1 | 1996 | 14 | 0.140 |
Why?
|
| Sex Factors | 9 | 2014 | 1285 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1135 | 0.140 |
Why?
|
| Oxygen | 2 | 2020 | 555 | 0.140 |
Why?
|
| RNA Viruses | 7 | 1980 | 36 | 0.140 |
Why?
|
| Mycobacterium Infections | 2 | 1987 | 31 | 0.140 |
Why?
|
| Polymorphism, Genetic | 4 | 2005 | 812 | 0.140 |
Why?
|
| Esophageal Achalasia | 2 | 1992 | 36 | 0.140 |
Why?
|
| Pseudomonas Infections | 3 | 2010 | 115 | 0.140 |
Why?
|
| Diagnosis, Differential | 9 | 2015 | 1893 | 0.140 |
Why?
|
| Kidney Diseases | 3 | 2018 | 481 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 9 | 2008 | 260 | 0.130 |
Why?
|
| Food Supply | 1 | 2017 | 100 | 0.130 |
Why?
|
| Contraceptives, Oral | 2 | 1995 | 37 | 0.130 |
Why?
|
| Transcriptional Activation | 3 | 2014 | 486 | 0.130 |
Why?
|
| Ethanol | 3 | 1994 | 163 | 0.130 |
Why?
|
| Polyomavirus Infections | 2 | 2009 | 90 | 0.130 |
Why?
|
| Peroxidases | 1 | 1996 | 26 | 0.130 |
Why?
|
| Clinical Protocols | 2 | 2008 | 236 | 0.130 |
Why?
|
| Pyrazoles | 4 | 2009 | 307 | 0.130 |
Why?
|
| Oncogene Proteins | 1 | 2017 | 137 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2008 | 938 | 0.130 |
Why?
|
| Carbon Radioisotopes | 3 | 2003 | 71 | 0.130 |
Why?
|
| Gerbillinae | 7 | 2011 | 55 | 0.130 |
Why?
|
| Barium Sulfate | 3 | 1997 | 12 | 0.130 |
Why?
|
| Mutagenesis | 2 | 2010 | 347 | 0.130 |
Why?
|
| Kallikreins | 1 | 2016 | 26 | 0.130 |
Why?
|
| Beverages | 1 | 1996 | 100 | 0.130 |
Why?
|
| Ammonia | 2 | 1993 | 74 | 0.130 |
Why?
|
| Hemostatic Techniques | 1 | 1996 | 32 | 0.130 |
Why?
|
| Ampicillin | 1 | 1996 | 58 | 0.130 |
Why?
|
| Laser Therapy | 1 | 1998 | 250 | 0.130 |
Why?
|
| Gastric Fundus | 3 | 2006 | 9 | 0.130 |
Why?
|
| Food Preferences | 1 | 1996 | 117 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 1996 | 47 | 0.130 |
Why?
|
| Health Priorities | 1 | 2016 | 36 | 0.130 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 1465 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2018 | 551 | 0.130 |
Why?
|
| Food | 3 | 1993 | 125 | 0.130 |
Why?
|
| Propensity Score | 2 | 2018 | 213 | 0.130 |
Why?
|
| Oscillometry | 1 | 2015 | 15 | 0.120 |
Why?
|
| Kinetics | 8 | 2023 | 1325 | 0.120 |
Why?
|
| Regression Analysis | 7 | 2005 | 778 | 0.120 |
Why?
|
| Pathology | 1 | 2015 | 39 | 0.120 |
Why?
|
| Toll-Like Receptor 10 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Vibration | 1 | 2015 | 32 | 0.120 |
Why?
|
| Electromagnetic Fields | 1 | 2015 | 26 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 121 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2016 | 229 | 0.120 |
Why?
|
| Operative Time | 1 | 2016 | 167 | 0.120 |
Why?
|
| Liver Neoplasms | 5 | 2008 | 1319 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2014 | 2304 | 0.120 |
Why?
|
| Organ Culture Techniques | 1 | 2015 | 154 | 0.120 |
Why?
|
| Polyvinyls | 1 | 1995 | 13 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1027 | 0.120 |
Why?
|
| Gene Expression Regulation | 7 | 2015 | 2538 | 0.120 |
Why?
|
| Drug Costs | 2 | 2008 | 60 | 0.120 |
Why?
|
| Blood Cells | 1 | 2015 | 49 | 0.120 |
Why?
|
| Bayes Theorem | 4 | 2023 | 283 | 0.120 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2015 | 33 | 0.120 |
Why?
|
| Sucralfate | 3 | 1990 | 5 | 0.120 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 1994 | 9 | 0.120 |
Why?
|
| Antibodies | 3 | 2014 | 372 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2012 | 339 | 0.120 |
Why?
|
| Azithromycin | 1 | 1995 | 44 | 0.120 |
Why?
|
| Immunoblotting | 6 | 2008 | 313 | 0.120 |
Why?
|
| Antimony | 2 | 1991 | 11 | 0.120 |
Why?
|
| Microarray Analysis | 4 | 2017 | 230 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 90 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 47 | 0.120 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 127 | 0.120 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 768 | 0.120 |
Why?
|
| Bacterial Secretion Systems | 1 | 2014 | 3 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 257 | 0.120 |
Why?
|
| Body Mass Index | 4 | 2012 | 1568 | 0.120 |
Why?
|
| Mice | 10 | 2018 | 17746 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2017 | 333 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 237 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2014 | 1708 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 1994 | 18 | 0.120 |
Why?
|
| Microbiota | 2 | 2017 | 390 | 0.120 |
Why?
|
| Anesthesia Recovery Period | 1 | 2014 | 23 | 0.120 |
Why?
|
| Colonic Diseases | 2 | 2013 | 38 | 0.120 |
Why?
|
| Endoscopes | 4 | 1990 | 20 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 549 | 0.110 |
Why?
|
| Spectrophotometry, Infrared | 2 | 2005 | 20 | 0.110 |
Why?
|
| Iron, Dietary | 2 | 2011 | 16 | 0.110 |
Why?
|
| History, 17th Century | 1 | 2014 | 35 | 0.110 |
Why?
|
| Ascites | 3 | 1988 | 88 | 0.110 |
Why?
|
| Cells, Cultured | 11 | 2019 | 3061 | 0.110 |
Why?
|
| Geography | 5 | 2007 | 110 | 0.110 |
Why?
|
| Medical Records | 2 | 2007 | 191 | 0.110 |
Why?
|
| History, 18th Century | 1 | 2014 | 70 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2001 | 658 | 0.110 |
Why?
|
| Cholera Vaccines | 1 | 2014 | 5 | 0.110 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 97 | 0.110 |
Why?
|
| Pepsin A | 3 | 1996 | 12 | 0.110 |
Why?
|
| Video Recording | 2 | 2005 | 183 | 0.110 |
Why?
|
| Salmonella Vaccines | 1 | 2013 | 7 | 0.110 |
Why?
|
| Transcriptome | 2 | 2017 | 937 | 0.110 |
Why?
|
| Arteries | 2 | 2013 | 219 | 0.110 |
Why?
|
| Erythrocytes | 3 | 1991 | 214 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2625 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2014 | 116 | 0.110 |
Why?
|
| Salmonella typhi | 1 | 2013 | 16 | 0.110 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2013 | 4 | 0.110 |
Why?
|
| Gastroscopes | 3 | 1989 | 7 | 0.110 |
Why?
|
| Nutrition Surveys | 2 | 2005 | 293 | 0.110 |
Why?
|
| United Kingdom | 4 | 2021 | 191 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2014 | 153 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 3142 | 0.110 |
Why?
|
| Electrocoagulation | 1 | 1993 | 36 | 0.110 |
Why?
|
| Social Environment | 1 | 1994 | 120 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 43 | 0.110 |
Why?
|
| Signal Transduction | 8 | 2018 | 4542 | 0.110 |
Why?
|
| Organoids | 1 | 2016 | 284 | 0.110 |
Why?
|
| Autophagy | 1 | 2017 | 395 | 0.110 |
Why?
|
| Drug Resistance | 4 | 2020 | 256 | 0.110 |
Why?
|
| Pyloric Stenosis | 2 | 1987 | 10 | 0.110 |
Why?
|
| Aging | 6 | 2007 | 1189 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2014 | 238 | 0.110 |
Why?
|
| Adrenal Glands | 2 | 1992 | 43 | 0.110 |
Why?
|
| Educational Status | 5 | 2007 | 274 | 0.110 |
Why?
|
| Water Supply | 3 | 2002 | 25 | 0.110 |
Why?
|
| Giardia lamblia | 1 | 1993 | 10 | 0.110 |
Why?
|
| Drug Combinations | 4 | 2007 | 266 | 0.110 |
Why?
|
| Acute Disease | 6 | 2019 | 1109 | 0.110 |
Why?
|
| Veterans Health | 1 | 2015 | 176 | 0.110 |
Why?
|
| Gene Frequency | 2 | 2013 | 719 | 0.110 |
Why?
|
| Disease Resistance | 1 | 2013 | 23 | 0.100 |
Why?
|
| Bicarbonates | 2 | 1991 | 98 | 0.100 |
Why?
|
| DNA Repair | 2 | 2010 | 587 | 0.100 |
Why?
|
| Dental Auxiliaries | 1 | 1992 | 2 | 0.100 |
Why?
|
| Dentists | 1 | 1992 | 7 | 0.100 |
Why?
|
| Cryptosporidium | 1 | 1993 | 31 | 0.100 |
Why?
|
| Rectum | 1 | 2013 | 99 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 52 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2013 | 37 | 0.100 |
Why?
|
| Nucleic Acids | 1 | 2013 | 23 | 0.100 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 428 | 0.100 |
Why?
|
| Subcutaneous Fat | 1 | 2013 | 29 | 0.100 |
Why?
|
| Intra-Abdominal Fat | 1 | 2013 | 51 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2017 | 510 | 0.100 |
Why?
|
| Vascular System Injuries | 1 | 2013 | 54 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 54 | 0.100 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2012 | 11 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2013 | 90 | 0.100 |
Why?
|
| Pan troglodytes | 1 | 1992 | 71 | 0.100 |
Why?
|
| Intubation, Gastrointestinal | 2 | 1991 | 52 | 0.100 |
Why?
|
| Papio | 1 | 1992 | 60 | 0.100 |
Why?
|
| Phosphatidylcholines | 1 | 2012 | 37 | 0.100 |
Why?
|
| Bhutan | 3 | 2017 | 21 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 431 | 0.100 |
Why?
|
| MicroRNAs | 2 | 2020 | 842 | 0.100 |
Why?
|
| Genetic Markers | 5 | 2020 | 606 | 0.100 |
Why?
|
| Indomethacin | 1 | 2012 | 84 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2014 | 177 | 0.100 |
Why?
|
| Pyrimidinones | 1 | 2012 | 40 | 0.100 |
Why?
|
| Decision Making | 2 | 2010 | 654 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 164 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2013 | 116 | 0.100 |
Why?
|
| Transformation, Bacterial | 2 | 2003 | 11 | 0.100 |
Why?
|
| Guanidines | 2 | 1982 | 25 | 0.100 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2013 | 32 | 0.100 |
Why?
|
| Drinking Water | 1 | 2012 | 12 | 0.100 |
Why?
|
| Hemagglutination, Viral | 1 | 2011 | 10 | 0.100 |
Why?
|
| Tissue Preservation | 1 | 2012 | 15 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 1992 | 75 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2017 | 1348 | 0.100 |
Why?
|
| Cell Count | 3 | 2020 | 252 | 0.100 |
Why?
|
| Peptide Hydrolases | 2 | 2012 | 141 | 0.100 |
Why?
|
| Magnesium Hydroxide | 3 | 2007 | 3 | 0.100 |
Why?
|
| Interleukin-11 | 1 | 2011 | 7 | 0.100 |
Why?
|
| Jurisprudence | 1 | 2011 | 14 | 0.100 |
Why?
|
| Receptors, Immunologic | 2 | 1989 | 113 | 0.100 |
Why?
|
| Actins | 2 | 2011 | 342 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 70 | 0.090 |
Why?
|
| Aluminum Hydroxide | 3 | 2007 | 40 | 0.090 |
Why?
|
| Esophagitis | 4 | 2004 | 40 | 0.090 |
Why?
|
| Paxillin | 1 | 2011 | 10 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 365 | 0.090 |
Why?
|
| Interferon-gamma | 4 | 2013 | 503 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 359 | 0.090 |
Why?
|
| Bombesin | 1 | 1991 | 4 | 0.090 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 24 | 0.090 |
Why?
|
| Cephalosporins | 1 | 1992 | 137 | 0.090 |
Why?
|
| Fluoroimmunoassay | 1 | 2011 | 6 | 0.090 |
Why?
|
| Duodenoscopy | 4 | 1997 | 13 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 5 | 2011 | 1761 | 0.090 |
Why?
|
| Genetic Variation | 6 | 2016 | 1493 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2013 | 701 | 0.090 |
Why?
|
| Linear Models | 2 | 2020 | 677 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2007 | 1017 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 93 | 0.090 |
Why?
|
| Plants, Medicinal | 2 | 1991 | 24 | 0.090 |
Why?
|
| Pentagastrin | 3 | 1999 | 6 | 0.090 |
Why?
|
| Culture Techniques | 3 | 2001 | 90 | 0.090 |
Why?
|
| Depression | 1 | 2020 | 1244 | 0.090 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1991 | 3 | 0.090 |
Why?
|
| Child Day Care Centers | 3 | 2002 | 25 | 0.090 |
Why?
|
| Pneumoperitoneum | 1 | 1991 | 11 | 0.090 |
Why?
|
| London | 2 | 2024 | 12 | 0.090 |
Why?
|
| Neutralization Tests | 4 | 2005 | 237 | 0.090 |
Why?
|
| Germany | 3 | 2020 | 66 | 0.090 |
Why?
|
| Powders | 2 | 2021 | 25 | 0.090 |
Why?
|
| Nizatidine | 2 | 2003 | 4 | 0.090 |
Why?
|
| Campylobacter fetus | 2 | 1988 | 3 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 723 | 0.090 |
Why?
|
| Chemokine CXCL1 | 2 | 2018 | 18 | 0.090 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 466 | 0.090 |
Why?
|
| Ireland | 2 | 2021 | 28 | 0.090 |
Why?
|
| Ablation Techniques | 1 | 2010 | 31 | 0.090 |
Why?
|
| Common Bile Duct | 2 | 2010 | 14 | 0.090 |
Why?
|
| Silver Compounds | 1 | 1990 | 6 | 0.090 |
Why?
|
| FMN Reductase | 2 | 2000 | 7 | 0.090 |
Why?
|
| Pregnancy | 4 | 2023 | 7172 | 0.090 |
Why?
|
| Multigene Family | 1 | 2011 | 297 | 0.090 |
Why?
|
| Serum | 1 | 2010 | 47 | 0.090 |
Why?
|
| Molecular Weight | 10 | 2003 | 392 | 0.090 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2010 | 10 | 0.090 |
Why?
|
| Fiber Optic Technology | 8 | 1986 | 46 | 0.090 |
Why?
|
| Gastrostomy | 2 | 1991 | 85 | 0.090 |
Why?
|
| Lipase | 3 | 1997 | 89 | 0.090 |
Why?
|
| Liver | 3 | 1995 | 1764 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 290 | 0.090 |
Why?
|
| Hydrolysis | 2 | 2001 | 163 | 0.090 |
Why?
|
| RNA | 1 | 2014 | 568 | 0.090 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 61 | 0.090 |
Why?
|
| Immunoglobulin M | 3 | 2005 | 212 | 0.090 |
Why?
|
| Watchful Waiting | 1 | 2010 | 69 | 0.090 |
Why?
|
| Blood Group Antigens | 1 | 2011 | 73 | 0.090 |
Why?
|
| Arachidonic Acids | 1 | 1990 | 29 | 0.090 |
Why?
|
| Bacterial Toxins | 2 | 2008 | 175 | 0.090 |
Why?
|
| Sex Distribution | 4 | 2004 | 301 | 0.090 |
Why?
|
| Loss of Heterozygosity | 2 | 2001 | 125 | 0.090 |
Why?
|
| Vietnam | 2 | 2000 | 45 | 0.090 |
Why?
|
| Choledocholithiasis | 1 | 2010 | 15 | 0.090 |
Why?
|
| Life Style | 2 | 2007 | 415 | 0.090 |
Why?
|
| Sequence Deletion | 2 | 2009 | 528 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2012 | 687 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 43 | 0.080 |
Why?
|
| Epithelium | 6 | 2000 | 362 | 0.080 |
Why?
|
| Placebo Effect | 1 | 2009 | 25 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 646 | 0.080 |
Why?
|
| Probability | 2 | 2008 | 323 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 487 | 0.080 |
Why?
|
| Blood Transfusion | 2 | 2010 | 308 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2006 | 53 | 0.080 |
Why?
|
| Mallory-Weiss Syndrome | 2 | 1980 | 3 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 366 | 0.080 |
Why?
|
| Disease Transmission, Infectious | 2 | 2008 | 86 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 184 | 0.080 |
Why?
|
| Body Water | 2 | 1993 | 90 | 0.080 |
Why?
|
| Polyomavirus | 1 | 2009 | 32 | 0.080 |
Why?
|
| Reoviridae | 5 | 1982 | 37 | 0.080 |
Why?
|
| Mycobacterium avium Complex | 2 | 2001 | 17 | 0.080 |
Why?
|
| Social Class | 5 | 2015 | 193 | 0.080 |
Why?
|
| Peptides | 4 | 2006 | 794 | 0.080 |
Why?
|
| Species Specificity | 6 | 2011 | 550 | 0.080 |
Why?
|
| Rats | 6 | 2012 | 3689 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 443 | 0.080 |
Why?
|
| Meptazinol | 1 | 1989 | 1 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 218 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2005 | 255 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2009 | 62 | 0.080 |
Why?
|
| Carrier State | 1 | 2009 | 77 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 86 | 0.080 |
Why?
|
| Hepatitis A | 2 | 2003 | 32 | 0.080 |
Why?
|
| Hemagglutination | 1 | 1988 | 8 | 0.080 |
Why?
|
| Thiazoles | 2 | 1989 | 97 | 0.080 |
Why?
|
| Disposable Equipment | 1 | 2008 | 17 | 0.080 |
Why?
|
| Dissection | 1 | 2009 | 53 | 0.080 |
Why?
|
| Evans Blue | 1 | 1988 | 1 | 0.080 |
Why?
|
| Azo Compounds | 1 | 1988 | 8 | 0.080 |
Why?
|
| Famotidine | 3 | 2004 | 9 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2012 | 1624 | 0.080 |
Why?
|
| Penicillin Resistance | 2 | 1999 | 80 | 0.080 |
Why?
|
| Ileum | 4 | 1987 | 132 | 0.080 |
Why?
|
| Iron Chelating Agents | 1 | 1988 | 14 | 0.080 |
Why?
|
| Oxazoles | 1 | 1988 | 23 | 0.080 |
Why?
|
| Azepines | 1 | 1989 | 62 | 0.080 |
Why?
|
| Viral Plaque Assay | 3 | 1991 | 42 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 64 | 0.080 |
Why?
|
| Cytochalasin D | 1 | 2008 | 12 | 0.080 |
Why?
|
| Pancreatic Elastase | 2 | 1996 | 13 | 0.080 |
Why?
|
| Alcian Blue | 2 | 1998 | 3 | 0.080 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2008 | 13 | 0.080 |
Why?
|
| Observer Variation | 2 | 2007 | 299 | 0.080 |
Why?
|
| Imidazoles | 1 | 2009 | 194 | 0.080 |
Why?
|
| Penicillin-Binding Proteins | 3 | 2003 | 14 | 0.070 |
Why?
|
| Colicins | 1 | 1988 | 4 | 0.070 |
Why?
|
| Virion | 3 | 1999 | 148 | 0.070 |
Why?
|
| Integrin beta1 | 1 | 2008 | 53 | 0.070 |
Why?
|
| Institutional Management Teams | 1 | 2007 | 3 | 0.070 |
Why?
|
| DNA Fragmentation | 1 | 2008 | 54 | 0.070 |
Why?
|
| Reference Standards | 2 | 2001 | 238 | 0.070 |
Why?
|
| Genistein | 1 | 2008 | 39 | 0.070 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2007 | 23 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2017 | 867 | 0.070 |
Why?
|
| DNA Probes | 4 | 1998 | 124 | 0.070 |
Why?
|
| Television | 2 | 1986 | 72 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2002 | 250 | 0.070 |
Why?
|
| Esophagoplasty | 1 | 1987 | 12 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2008 | 133 | 0.070 |
Why?
|
| Pancreatic Diseases | 2 | 1979 | 39 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 1988 | 132 | 0.070 |
Why?
|
| Intrauterine Devices | 1 | 2007 | 14 | 0.070 |
Why?
|
| Artifacts | 1 | 2008 | 109 | 0.070 |
Why?
|
| Neutrophil Activation | 2 | 1999 | 16 | 0.070 |
Why?
|
| Physician Executives | 1 | 2007 | 40 | 0.070 |
Why?
|
| Chromosomes, Bacterial | 1 | 1988 | 64 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 2 | 2002 | 324 | 0.070 |
Why?
|
| Acids | 3 | 2005 | 28 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 141 | 0.070 |
Why?
|
| Cardiac Tamponade | 1 | 1987 | 37 | 0.070 |
Why?
|
| Silicic Acid | 1 | 2007 | 1 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 825 | 0.070 |
Why?
|
| International Cooperation | 1 | 2008 | 157 | 0.070 |
Why?
|
| Trypsin | 5 | 1981 | 96 | 0.070 |
Why?
|
| Capsicum | 1 | 1987 | 3 | 0.070 |
Why?
|
| Freezing | 2 | 2005 | 28 | 0.070 |
Why?
|
| Models, Educational | 1 | 2007 | 74 | 0.070 |
Why?
|
| Asthma | 1 | 2015 | 748 | 0.070 |
Why?
|
| Pain | 2 | 1989 | 459 | 0.070 |
Why?
|
| Nematode Infections | 1 | 1987 | 6 | 0.070 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1987 | 25 | 0.070 |
Why?
|
| Genes, Viral | 5 | 1990 | 185 | 0.070 |
Why?
|
| Nematoda | 1 | 1987 | 16 | 0.070 |
Why?
|
| Mucous Membrane | 3 | 2015 | 88 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 1998 | 1247 | 0.070 |
Why?
|
| Secondary Prevention | 2 | 2019 | 217 | 0.070 |
Why?
|
| Cell Division | 3 | 2005 | 782 | 0.070 |
Why?
|
| Mucin-6 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Peptic Ulcer Perforation | 3 | 2002 | 16 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2008 | 459 | 0.070 |
Why?
|
| Translocation, Genetic | 1 | 2009 | 356 | 0.070 |
Why?
|
| Internationality | 2 | 2019 | 131 | 0.070 |
Why?
|
| In Vitro Techniques | 4 | 2000 | 973 | 0.070 |
Why?
|
| Sigmoid Diseases | 2 | 1987 | 7 | 0.070 |
Why?
|
| Mucin 5AC | 1 | 2006 | 24 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2007 | 178 | 0.070 |
Why?
|
| Iron Metabolism Disorders | 1 | 2006 | 13 | 0.070 |
Why?
|
| Mucin-2 | 1 | 2006 | 40 | 0.070 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1987 | 46 | 0.070 |
Why?
|
| Virus Diseases | 2 | 1979 | 279 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2010 | 8182 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1898 | 0.070 |
Why?
|
| Hiccup | 1 | 1986 | 6 | 0.070 |
Why?
|
| Diagnostic Errors | 3 | 2009 | 332 | 0.070 |
Why?
|
| Interleukin-10 | 3 | 2014 | 173 | 0.070 |
Why?
|
| Dominican Republic | 2 | 2017 | 16 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 240 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2006 | 26 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 144 | 0.070 |
Why?
|
| Sputum | 1 | 1987 | 105 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 1291 | 0.070 |
Why?
|
| B7-1 Antigen | 1 | 2006 | 12 | 0.070 |
Why?
|
| Escherichia coli Proteins | 1 | 1988 | 305 | 0.070 |
Why?
|
| Capsid | 3 | 1994 | 142 | 0.060 |
Why?
|
| DNA Restriction Enzymes | 2 | 2004 | 120 | 0.060 |
Why?
|
| Prostheses and Implants | 2 | 1987 | 150 | 0.060 |
Why?
|
| Rodent Diseases | 1 | 1985 | 17 | 0.060 |
Why?
|
| Sepsis | 1 | 2010 | 479 | 0.060 |
Why?
|
| DNA Gyrase | 2 | 2016 | 22 | 0.060 |
Why?
|
| Ghrelin | 1 | 2006 | 54 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 1674 | 0.060 |
Why?
|
| Sulindac | 1 | 1985 | 5 | 0.060 |
Why?
|
| Indenes | 1 | 1985 | 10 | 0.060 |
Why?
|
| Premedication | 1 | 1985 | 43 | 0.060 |
Why?
|
| Mast Cells | 2 | 1997 | 74 | 0.060 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 54 | 0.060 |
Why?
|
| Cotinine | 1 | 2005 | 23 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2007 | 160 | 0.060 |
Why?
|
| HIV Infections | 2 | 2014 | 1896 | 0.060 |
Why?
|
| Prostaglandins E | 1 | 1985 | 8 | 0.060 |
Why?
|
| Infusion Pumps | 1 | 2005 | 33 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 1425 | 0.060 |
Why?
|
| Algorithms | 2 | 2009 | 1616 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2008 | 615 | 0.060 |
Why?
|
| Food, Formulated | 1 | 1985 | 52 | 0.060 |
Why?
|
| Cheese | 1 | 2025 | 7 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2015 | 294 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 389 | 0.060 |
Why?
|
| Peptide Hormones | 1 | 2006 | 68 | 0.060 |
Why?
|
| Coculture Techniques | 3 | 2015 | 233 | 0.060 |
Why?
|
| Mucus | 1 | 2005 | 36 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2005 | 53 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2013 | 283 | 0.060 |
Why?
|
| Transcription, Genetic | 8 | 2007 | 1704 | 0.060 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2005 | 26 | 0.060 |
Why?
|
| Hemostasis | 1 | 2005 | 70 | 0.060 |
Why?
|
| Choristoma | 2 | 2003 | 49 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2090 | 0.060 |
Why?
|
| Immunity, Mucosal | 3 | 2000 | 87 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2014 | 143 | 0.060 |
Why?
|
| Blotting, Southern | 4 | 1998 | 215 | 0.060 |
Why?
|
| Anesthesia, Local | 1 | 2005 | 48 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 316 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 1985 | 81 | 0.060 |
Why?
|
| ABO Blood-Group System | 2 | 2002 | 66 | 0.060 |
Why?
|
| Threonine | 1 | 2004 | 59 | 0.060 |
Why?
|
| Aluminum | 1 | 1984 | 11 | 0.060 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2004 | 15 | 0.060 |
Why?
|
| Cholestyramine Resin | 2 | 2000 | 13 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 792 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 4431 | 0.060 |
Why?
|
| Acetaminophen | 1 | 1985 | 92 | 0.060 |
Why?
|
| Tumor Virus Infections | 1 | 2005 | 133 | 0.060 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2004 | 121 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 1985 | 79 | 0.060 |
Why?
|
| Water Microbiology | 2 | 1996 | 24 | 0.060 |
Why?
|
| Protein Precursors | 5 | 1993 | 153 | 0.060 |
Why?
|
| Electrosurgery | 1 | 2004 | 17 | 0.060 |
Why?
|
| Sulfoxides | 1 | 2003 | 10 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2005 | 80 | 0.060 |
Why?
|
| Simian virus 40 | 1 | 2005 | 199 | 0.060 |
Why?
|
| Alanine | 1 | 2004 | 181 | 0.060 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2017 | 158 | 0.060 |
Why?
|
| Phenolphthaleins | 1 | 1983 | 1 | 0.060 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2003 | 9 | 0.060 |
Why?
|
| Occult Blood | 1 | 1984 | 33 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 530 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 75 | 0.050 |
Why?
|
| Stents | 1 | 2010 | 882 | 0.050 |
Why?
|
| Endothelium, Vascular | 3 | 1996 | 523 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 411 | 0.050 |
Why?
|
| Dairying | 1 | 2023 | 2 | 0.050 |
Why?
|
| Pseudomonas | 1 | 1983 | 11 | 0.050 |
Why?
|
| Farms | 1 | 2023 | 3 | 0.050 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2003 | 11 | 0.050 |
Why?
|
| Tunicamycin | 1 | 1983 | 7 | 0.050 |
Why?
|
| Glucosamine | 1 | 1983 | 12 | 0.050 |
Why?
|
| Hospitalization | 2 | 2010 | 1783 | 0.050 |
Why?
|
| Uterus | 1 | 2007 | 570 | 0.050 |
Why?
|
| Swine | 5 | 1991 | 1173 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2023 | 60 | 0.050 |
Why?
|
| Diclofenac | 1 | 2002 | 6 | 0.050 |
Why?
|
| Nitroimidazoles | 2 | 2016 | 45 | 0.050 |
Why?
|
| Bacterial Typing Techniques | 1 | 2003 | 102 | 0.050 |
Why?
|
| Antigenic Variation | 1 | 2003 | 39 | 0.050 |
Why?
|
| Hepatitis C | 1 | 2007 | 365 | 0.050 |
Why?
|
| Permeability | 1 | 2003 | 119 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 88 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2004 | 383 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 39 | 0.050 |
Why?
|
| Niacin | 1 | 1983 | 58 | 0.050 |
Why?
|
| Alginates | 1 | 2022 | 18 | 0.050 |
Why?
|
| Viruses | 1 | 1984 | 123 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 1110 | 0.050 |
Why?
|
| Reward | 1 | 2023 | 110 | 0.050 |
Why?
|
| Irritants | 1 | 2002 | 7 | 0.050 |
Why?
|
| Base Pair Mismatch | 1 | 2002 | 21 | 0.050 |
Why?
|
| Gene Expression | 3 | 2004 | 1570 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 327 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 2 | 2000 | 147 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2002 | 40 | 0.050 |
Why?
|
| Hygiene | 1 | 2002 | 25 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 1982 | 74 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2001 | 303 | 0.050 |
Why?
|
| Magnesium | 1 | 1982 | 121 | 0.050 |
Why?
|
| Chemokines | 1 | 2002 | 135 | 0.050 |
Why?
|
| Office Visits | 1 | 2002 | 77 | 0.050 |
Why?
|
| Gastric Mucins | 2 | 1998 | 5 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2003 | 187 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 404 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2002 | 145 | 0.050 |
Why?
|
| Intestinal Fistula | 1 | 1982 | 28 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 548 | 0.050 |
Why?
|
| Autoantigens | 1 | 2002 | 119 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2003 | 139 | 0.050 |
Why?
|
| Immunoassay | 3 | 2012 | 130 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 14 | 0.050 |
Why?
|
| Fistula | 1 | 1982 | 50 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 218 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 254 | 0.050 |
Why?
|
| ROC Curve | 2 | 2010 | 565 | 0.050 |
Why?
|
| Iliac Artery | 1 | 1982 | 93 | 0.050 |
Why?
|
| Constipation | 1 | 1982 | 115 | 0.050 |
Why?
|
| Capillary Permeability | 2 | 1994 | 76 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2007 | 1022 | 0.050 |
Why?
|
| Aquaculture | 1 | 2021 | 6 | 0.050 |
Why?
|
| DNA, Viral | 3 | 2009 | 480 | 0.050 |
Why?
|
| Barium Compounds | 1 | 2021 | 6 | 0.050 |
Why?
|
| Factor Xa Inhibitors | 1 | 2022 | 65 | 0.050 |
Why?
|
| Spheroplasts | 1 | 2000 | 2 | 0.050 |
Why?
|
| Kazakhstan | 3 | 2007 | 8 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2004 | 441 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2001 | 319 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2003 | 374 | 0.050 |
Why?
|
| Tuberculosis | 2 | 1999 | 519 | 0.050 |
Why?
|
| Health Maintenance Organizations | 2 | 2013 | 22 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2021 | 68 | 0.040 |
Why?
|
| Monocytes | 2 | 2002 | 354 | 0.040 |
Why?
|
| Neuraminidase | 2 | 1992 | 36 | 0.040 |
Why?
|
| Haplorhini | 10 | 1983 | 123 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 2000 | 87 | 0.040 |
Why?
|
| Peru | 3 | 1996 | 47 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 1988 | 880 | 0.040 |
Why?
|
| Enteral Nutrition | 2 | 1991 | 256 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2001 | 230 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 276 | 0.040 |
Why?
|
| Indoles | 1 | 2001 | 181 | 0.040 |
Why?
|
| Catheters | 1 | 2021 | 87 | 0.040 |
Why?
|
| Hepatitis B, Chronic | 1 | 2001 | 82 | 0.040 |
Why?
|
| alpha-Fetoproteins | 3 | 1993 | 132 | 0.040 |
Why?
|
| Cats | 2 | 1997 | 116 | 0.040 |
Why?
|
| DNA Transposable Elements | 1 | 2001 | 177 | 0.040 |
Why?
|
| France | 1 | 2020 | 79 | 0.040 |
Why?
|
| Pylorus | 2 | 1977 | 21 | 0.040 |
Why?
|
| Vasopressins | 1 | 1980 | 43 | 0.040 |
Why?
|
| Colostrum | 2 | 1999 | 54 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 199 | 0.040 |
Why?
|
| Glycochenodeoxycholic Acid | 1 | 2020 | 8 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2005 | 774 | 0.040 |
Why?
|
| Toothache | 1 | 1999 | 1 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2020 | 104 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 808 | 0.040 |
Why?
|
| Periodontitis | 1 | 1999 | 11 | 0.040 |
Why?
|
| Genome | 1 | 2002 | 476 | 0.040 |
Why?
|
| Microtomy | 1 | 1999 | 3 | 0.040 |
Why?
|
| Uranyl Nitrate | 1 | 1999 | 3 | 0.040 |
Why?
|
| Peritoneal Diseases | 1 | 1979 | 9 | 0.040 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2020 | 42 | 0.040 |
Why?
|
| Ampicillin Resistance | 1 | 1999 | 17 | 0.040 |
Why?
|
| Markov Chains | 1 | 2020 | 84 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 607 | 0.040 |
Why?
|
| Interleukin-12 | 2 | 1997 | 114 | 0.040 |
Why?
|
| Nitrates | 1 | 1999 | 28 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 33 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 46 | 0.040 |
Why?
|
| Lead | 1 | 1999 | 23 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 1999 | 37 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 112 | 0.040 |
Why?
|
| Leprosy | 1 | 1999 | 19 | 0.040 |
Why?
|
| Laparoscopy | 2 | 1988 | 490 | 0.040 |
Why?
|
| Duodenal Diseases | 2 | 1990 | 34 | 0.040 |
Why?
|
| Agricultural Workers' Diseases | 1 | 1999 | 14 | 0.040 |
Why?
|
| Glucans | 1 | 1999 | 11 | 0.040 |
Why?
|
| CD3 Complex | 1 | 1999 | 86 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2019 | 141 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 210 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2019 | 39 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 159 | 0.040 |
Why?
|
| Health Behavior | 1 | 2002 | 386 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 1999 | 97 | 0.040 |
Why?
|
| Epidemiologic Methods | 3 | 1991 | 110 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 48 | 0.040 |
Why?
|
| Minority Groups | 1 | 2001 | 251 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2019 | 60 | 0.040 |
Why?
|
| Lactation | 1 | 2020 | 194 | 0.040 |
Why?
|
| Twins, Dizygotic | 2 | 2000 | 42 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1999 | 70 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 1019 | 0.040 |
Why?
|
| Rosaniline Dyes | 1 | 1998 | 4 | 0.040 |
Why?
|
| Palliative Care | 2 | 1998 | 429 | 0.040 |
Why?
|
| Hematoxylin | 1 | 1998 | 8 | 0.040 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1998 | 9 | 0.040 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 1998 | 7 | 0.040 |
Why?
|
| Buffers | 2 | 1990 | 31 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 1999 | 330 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 1978 | 60 | 0.040 |
Why?
|
| Gastrointestinal Contents | 2 | 1988 | 12 | 0.040 |
Why?
|
| Fluoroscopy | 2 | 1991 | 91 | 0.040 |
Why?
|
| Doxycycline | 1 | 1999 | 117 | 0.040 |
Why?
|
| Cholestasis | 3 | 2010 | 154 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 2058 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 267 | 0.040 |
Why?
|
| Liver Cirrhosis | 2 | 2002 | 834 | 0.040 |
Why?
|
| Disease Outbreaks | 2 | 1984 | 323 | 0.040 |
Why?
|
| Azure Stains | 1 | 1998 | 4 | 0.040 |
Why?
|
| Housing | 2 | 1996 | 59 | 0.040 |
Why?
|
| Health Status | 1 | 2000 | 374 | 0.040 |
Why?
|
| Medical Laboratory Personnel | 1 | 1998 | 9 | 0.040 |
Why?
|
| Information Services | 1 | 1998 | 21 | 0.040 |
Why?
|
| Histological Techniques | 1 | 1998 | 21 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 143 | 0.040 |
Why?
|
| Twins, Monozygotic | 2 | 2000 | 117 | 0.040 |
Why?
|
| Medical Laboratory Science | 1 | 1998 | 13 | 0.040 |
Why?
|
| Calcium | 3 | 1982 | 1098 | 0.040 |
Why?
|
| World Health Organization | 1 | 2018 | 100 | 0.040 |
Why?
|
| Pathology, Clinical | 1 | 1998 | 23 | 0.040 |
Why?
|
| Urban Health | 1 | 2018 | 76 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2017 | 400 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 196 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2013 | 1327 | 0.040 |
Why?
|
| Baculoviridae | 2 | 1994 | 64 | 0.040 |
Why?
|
| Meat | 3 | 2000 | 48 | 0.040 |
Why?
|
| Sanitation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 1999 | 321 | 0.040 |
Why?
|
| Oceania | 1 | 2017 | 4 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 1980 | 224 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 204 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1998 | 356 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1997 | 52 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2007 | 1177 | 0.030 |
Why?
|
| Bahrain | 1 | 2017 | 3 | 0.030 |
Why?
|
| Membrane Potentials | 2 | 1990 | 304 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 292 | 0.030 |
Why?
|
| Colon, Sigmoid | 1 | 1977 | 13 | 0.030 |
Why?
|
| Zoonoses | 1 | 1997 | 44 | 0.030 |
Why?
|
| Dietary Supplements | 2 | 2011 | 477 | 0.030 |
Why?
|
| Haplotypes | 2 | 2009 | 520 | 0.030 |
Why?
|
| Volunteers | 1 | 2017 | 25 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 338 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1998 | 141 | 0.030 |
Why?
|
| Chaperonin 60 | 2 | 1997 | 32 | 0.030 |
Why?
|
| Vaccines, DNA | 1 | 1997 | 48 | 0.030 |
Why?
|
| Polynesia | 2 | 2009 | 4 | 0.030 |
Why?
|
| Benzidines | 1 | 1996 | 2 | 0.030 |
Why?
|
| Gels | 1 | 1996 | 68 | 0.030 |
Why?
|
| Orphanages | 1 | 1996 | 7 | 0.030 |
Why?
|
| Intestinal Perforation | 1 | 1977 | 60 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 1996 | 51 | 0.030 |
Why?
|
| Glycoproteins | 3 | 1983 | 370 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 1998 | 222 | 0.030 |
Why?
|
| Biological Transport | 1 | 1997 | 348 | 0.030 |
Why?
|
| Nicaragua | 1 | 2016 | 26 | 0.030 |
Why?
|
| Vaccination | 2 | 2014 | 952 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 1996 | 19 | 0.030 |
Why?
|
| Adenoma, Islet Cell | 1 | 1975 | 8 | 0.030 |
Why?
|
| Spodoptera | 1 | 1996 | 44 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 75 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 1996 | 29 | 0.030 |
Why?
|
| Aminopyrine | 1 | 1995 | 7 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2007 | 143 | 0.030 |
Why?
|
| Alcoholism | 2 | 1976 | 231 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2016 | 56 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 145 | 0.030 |
Why?
|
| Goats | 1 | 1995 | 55 | 0.030 |
Why?
|
| Cholangiography | 1 | 1975 | 14 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1996 | 427 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 1996 | 113 | 0.030 |
Why?
|
| Mixed Function Oxygenases | 1 | 1995 | 30 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2012 | 1229 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 1996 | 72 | 0.030 |
Why?
|
| Dental Staff | 1 | 1995 | 1 | 0.030 |
Why?
|
| Dentistry | 1 | 1995 | 5 | 0.030 |
Why?
|
| Adaptation, Physiological | 2 | 1988 | 272 | 0.030 |
Why?
|
| Liver Diseases | 1 | 1979 | 366 | 0.030 |
Why?
|
| Vomiting | 2 | 1992 | 107 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 521 | 0.030 |
Why?
|
| Diverticulum, Esophageal | 1 | 1975 | 3 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 257 | 0.030 |
Why?
|
| Pancreatic Cyst | 1 | 1975 | 30 | 0.030 |
Why?
|
| South Africa | 2 | 2008 | 100 | 0.030 |
Why?
|
| Equipment Safety | 1 | 1995 | 36 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2017 | 213 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 285 | 0.030 |
Why?
|
| Blood | 2 | 1989 | 105 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 35 | 0.030 |
Why?
|
| Photochemotherapy | 1 | 2015 | 35 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 355 | 0.030 |
Why?
|
| Blastomycosis | 1 | 1994 | 7 | 0.030 |
Why?
|
| Blood Platelets | 2 | 1994 | 327 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 1008 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2002 | 3753 | 0.030 |
Why?
|
| Alleles | 1 | 1999 | 1618 | 0.030 |
Why?
|
| Lipid A | 1 | 2014 | 23 | 0.030 |
Why?
|
| Language | 2 | 2009 | 204 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1994 | 43 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2015 | 173 | 0.030 |
Why?
|
| Stroke | 1 | 2002 | 986 | 0.030 |
Why?
|
| Acetaldehyde | 1 | 1994 | 8 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 821 | 0.030 |
Why?
|
| Potassium | 3 | 1987 | 280 | 0.030 |
Why?
|
| Child Rearing | 1 | 1994 | 28 | 0.030 |
Why?
|
| Histoplasmosis | 1 | 1994 | 47 | 0.030 |
Why?
|
| Gastrointestinal Motility | 3 | 1982 | 46 | 0.030 |
Why?
|
| Mumps | 1 | 1974 | 11 | 0.030 |
Why?
|
| Capillaries | 1 | 1994 | 66 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1994 | 40 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 122 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 1994 | 55 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1994 | 170 | 0.030 |
Why?
|
| Twin Studies as Topic | 1 | 1994 | 15 | 0.030 |
Why?
|
| Chile | 1 | 2014 | 21 | 0.030 |
Why?
|
| Albumins | 1 | 1994 | 88 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 95 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 1995 | 129 | 0.030 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1973 | 14 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 1996 | 240 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2013 | 106 | 0.030 |
Why?
|
| Causality | 1 | 1994 | 83 | 0.030 |
Why?
|
| Environment | 1 | 2014 | 145 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 20 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 232 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1993 | 113 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2013 | 173 | 0.030 |
Why?
|
| RNA, Double-Stranded | 2 | 1984 | 63 | 0.030 |
Why?
|
| Candidiasis | 1 | 1994 | 129 | 0.030 |
Why?
|
| Skin | 1 | 1996 | 512 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 2013 | 9 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 1973 | 48 | 0.030 |
Why?
|
| Pharmacovigilance | 1 | 2013 | 10 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2014 | 121 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 69 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1983 | 234 | 0.030 |
Why?
|
| Tricuspid Valve | 1 | 1973 | 59 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1993 | 356 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 112 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2010 | 166 | 0.030 |
Why?
|
| Cadaverine | 1 | 1992 | 4 | 0.030 |
Why?
|
| Cytochalasin B | 1 | 1992 | 9 | 0.030 |
Why?
|
| Ammonium Chloride | 1 | 1992 | 7 | 0.030 |
Why?
|
| Viral Load | 1 | 2014 | 385 | 0.030 |
Why?
|
| Human Experimentation | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1994 | 218 | 0.030 |
Why?
|
| Rural Population | 2 | 2008 | 257 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 1985 | 256 | 0.020 |
Why?
|
| RNA, Ribosomal | 1 | 1992 | 63 | 0.020 |
Why?
|
| Chloroquine | 1 | 1992 | 32 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 355 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2012 | 25 | 0.020 |
Why?
|
| CD18 Antigens | 3 | 1999 | 49 | 0.020 |
Why?
|
| Prebiotics | 1 | 2012 | 23 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1974 | 227 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 1973 | 133 | 0.020 |
Why?
|
| Hypertension | 2 | 2017 | 1314 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2000 | 826 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 296 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2012 | 94 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 2 | 2003 | 40 | 0.020 |
Why?
|
| Fimbriae, Bacterial | 1 | 1991 | 42 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2011 | 114 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1991 | 4 | 0.020 |
Why?
|
| Arkansas | 1 | 1991 | 58 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 1991 | 10 | 0.020 |
Why?
|
| Diarrhea, Infantile | 2 | 1983 | 36 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2011 | 135 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 244 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 229 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 791 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1991 | 151 | 0.020 |
Why?
|
| Sodium Azide | 1 | 1991 | 4 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1991 | 18 | 0.020 |
Why?
|
| Proteus mirabilis | 1 | 1991 | 12 | 0.020 |
Why?
|
| Substance-Related Disorders | 2 | 1973 | 459 | 0.020 |
Why?
|
| Azides | 1 | 1991 | 10 | 0.020 |
Why?
|
| Chromatography | 1 | 1991 | 43 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2011 | 54 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 1991 | 58 | 0.020 |
Why?
|
| Nickel | 1 | 1991 | 22 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 329 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 428 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1991 | 185 | 0.020 |
Why?
|
| Glass | 1 | 1990 | 12 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 577 | 0.020 |
Why?
|
| Saudi Arabia | 1 | 1990 | 38 | 0.020 |
Why?
|
| Fabaceae | 1 | 1991 | 24 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2012 | 667 | 0.020 |
Why?
|
| Lymphoma | 1 | 1994 | 323 | 0.020 |
Why?
|
| Silver | 1 | 1990 | 22 | 0.020 |
Why?
|
| Calibration | 1 | 1990 | 89 | 0.020 |
Why?
|
| Glutamine | 1 | 1991 | 211 | 0.020 |
Why?
|
| Drug Compounding | 1 | 1990 | 36 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1991 | 290 | 0.020 |
Why?
|
| RNA-Directed DNA Polymerase | 3 | 1997 | 46 | 0.020 |
Why?
|
| Klebsiella pneumoniae | 1 | 1991 | 73 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 868 | 0.020 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1990 | 40 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 807 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2000 | 1272 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1990 | 65 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 100 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1990 | 79 | 0.020 |
Why?
|
| Cell Movement | 2 | 1994 | 835 | 0.020 |
Why?
|
| Clostridium perfringens | 1 | 1989 | 7 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2010 | 141 | 0.020 |
Why?
|
| Suspensions | 1 | 1989 | 10 | 0.020 |
Why?
|
| Cell Adhesion | 3 | 1996 | 321 | 0.020 |
Why?
|
| Recombination, Genetic | 2 | 2003 | 449 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 1989 | 48 | 0.020 |
Why?
|
| Sweden | 2 | 2000 | 35 | 0.020 |
Why?
|
| Colonoscopes | 1 | 1989 | 9 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2009 | 4 | 0.020 |
Why?
|
| Melanesia | 1 | 2009 | 3 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 1989 | 34 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 317 | 0.020 |
Why?
|
| Needles | 1 | 1989 | 51 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2006 | 422 | 0.020 |
Why?
|
| Capsaicin | 1 | 1988 | 18 | 0.020 |
Why?
|
| Heme | 1 | 1989 | 53 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 3 | 1984 | 29 | 0.020 |
Why?
|
| Computer Systems | 1 | 1988 | 38 | 0.020 |
Why?
|
| Mannose | 1 | 1988 | 20 | 0.020 |
Why?
|
| Half-Life | 1 | 1989 | 157 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2007 | 930 | 0.020 |
Why?
|
| Australia | 1 | 2009 | 139 | 0.020 |
Why?
|
| Peritonitis, Tuberculous | 1 | 1988 | 4 | 0.020 |
Why?
|
| Protein Binding | 2 | 1993 | 1749 | 0.020 |
Why?
|
| Enterotoxins | 1 | 1988 | 82 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2008 | 58 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1988 | 36 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 36 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2008 | 20 | 0.020 |
Why?
|
| Vaccines, Inactivated | 1 | 1988 | 145 | 0.020 |
Why?
|
| Competitive Medical Plans | 1 | 2007 | 1 | 0.020 |
Why?
|
| Egypt | 1 | 2008 | 23 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 138 | 0.020 |
Why?
|
| Cell Membrane Permeability | 2 | 2005 | 74 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 626 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 27 | 0.020 |
Why?
|
| Dimerization | 1 | 2008 | 144 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 1987 | 18 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2008 | 48 | 0.020 |
Why?
|
| Luciferases | 1 | 2008 | 135 | 0.020 |
Why?
|
| Rhabdomyolysis | 1 | 2007 | 37 | 0.020 |
Why?
|
| Plants, Edible | 1 | 1987 | 3 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 199 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2007 | 90 | 0.020 |
Why?
|
| Binding Sites | 2 | 2005 | 1297 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 226 | 0.020 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2007 | 8 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2007 | 24 | 0.020 |
Why?
|
| Pericarditis | 1 | 1987 | 43 | 0.020 |
Why?
|
| Morbidity | 1 | 2008 | 244 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2009 | 211 | 0.020 |
Why?
|
| Swine, Miniature | 1 | 1987 | 46 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 41 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2010 | 686 | 0.020 |
Why?
|
| Interferon Regulatory Factors | 1 | 2007 | 38 | 0.020 |
Why?
|
| Glycolipids | 1 | 1986 | 32 | 0.020 |
Why?
|
| Pressure | 2 | 1978 | 128 | 0.020 |
Why?
|
| Mitochondria, Liver | 1 | 1986 | 31 | 0.020 |
Why?
|
| Transaminases | 1 | 1986 | 33 | 0.020 |
Why?
|
| Mosaicism | 1 | 2008 | 241 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2008 | 334 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 142 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 471 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 166 | 0.020 |
Why?
|
| Peristalsis | 1 | 1986 | 8 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 574 | 0.020 |
Why?
|
| raf Kinases | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2007 | 109 | 0.020 |
Why?
|
| Patient Admission | 1 | 1988 | 187 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 155 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 101 | 0.020 |
Why?
|
| Peritoneal Dialysis | 1 | 1988 | 119 | 0.020 |
Why?
|
| Acid-Base Imbalance | 2 | 1976 | 27 | 0.020 |
Why?
|
| Viral Structural Proteins | 5 | 1984 | 48 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2006 | 42 | 0.020 |
Why?
|
| Pancreatic Extracts | 1 | 1986 | 1 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 37 | 0.020 |
Why?
|
| Bacteremia | 1 | 2010 | 407 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2006 | 43 | 0.020 |
Why?
|
| Pyridines | 1 | 2007 | 230 | 0.020 |
Why?
|
| Epitopes | 2 | 1985 | 431 | 0.020 |
Why?
|
| Jejunum | 2 | 1984 | 128 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2013 | 725 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2006 | 62 | 0.020 |
Why?
|
| Animals, Laboratory | 1 | 1985 | 12 | 0.020 |
Why?
|
| Computers | 1 | 1986 | 68 | 0.020 |
Why?
|
| Education | 1 | 2006 | 107 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 207 | 0.020 |
Why?
|
| Benzalkonium Compounds | 1 | 1985 | 3 | 0.020 |
Why?
|
| Cetrimonium Compounds | 1 | 1985 | 4 | 0.020 |
Why?
|
| para-Aminobenzoates | 1 | 1985 | 5 | 0.020 |
Why?
|
| Benzocaine | 1 | 1985 | 5 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 91 | 0.020 |
Why?
|
| Mouthwashes | 1 | 1985 | 10 | 0.020 |
Why?
|
| Tetracaine | 1 | 1985 | 9 | 0.020 |
Why?
|
| Solutions | 1 | 1985 | 65 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 670 | 0.020 |
Why?
|
| Wound Healing | 1 | 1989 | 458 | 0.020 |
Why?
|
| Taste | 1 | 1985 | 31 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 49 | 0.020 |
Why?
|
| Lidocaine | 1 | 1985 | 48 | 0.020 |
Why?
|
| Enema | 1 | 1985 | 39 | 0.020 |
Why?
|
| ras Proteins | 1 | 2006 | 137 | 0.020 |
Why?
|
| Aerosols | 1 | 1985 | 65 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2006 | 226 | 0.020 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2005 | 12 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 91 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 317 | 0.020 |
Why?
|
| Hemagglutinins, Viral | 1 | 1985 | 25 | 0.020 |
Why?
|
| Antiporters | 1 | 2005 | 32 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2006 | 109 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2035 | 0.010 |
Why?
|
| Drug Contamination | 1 | 2005 | 37 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 130 | 0.010 |
Why?
|
| Pedigree | 1 | 2008 | 1595 | 0.010 |
Why?
|
| Western World | 1 | 2004 | 4 | 0.010 |
Why?
|
| CD11 Antigens | 2 | 1995 | 13 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1985 | 76 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 76 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 177 | 0.010 |
Why?
|
| Adsorption | 1 | 1984 | 32 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 316 | 0.010 |
Why?
|
| Anemia | 2 | 1986 | 340 | 0.010 |
Why?
|
| Cytotoxins | 1 | 1984 | 20 | 0.010 |
Why?
|
| Horseradish Peroxidase | 1 | 1984 | 14 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 239 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2005 | 137 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1984 | 132 | 0.010 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2003 | 23 | 0.010 |
Why?
|
| Phenolphthalein | 1 | 1983 | 1 | 0.010 |
Why?
|
| Chymotrypsin | 2 | 1981 | 16 | 0.010 |
Why?
|
| Antidiarrheals | 1 | 1983 | 17 | 0.010 |
Why?
|
| Bulgaria | 1 | 1983 | 4 | 0.010 |
Why?
|
| Gold | 1 | 1984 | 49 | 0.010 |
Why?
|
| Ileitis | 1 | 1983 | 10 | 0.010 |
Why?
|
| Endarterectomy | 1 | 2003 | 29 | 0.010 |
Why?
|
| Social Problems | 1 | 2003 | 3 | 0.010 |
Why?
|
| Czech Republic | 1 | 2003 | 11 | 0.010 |
Why?
|
| Agriculture | 1 | 2003 | 29 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 393 | 0.010 |
Why?
|
| Triolein | 1 | 1982 | 3 | 0.010 |
Why?
|
| Oleic Acids | 1 | 1982 | 10 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1985 | 833 | 0.010 |
Why?
|
| Hepatitis A Antibodies | 1 | 2002 | 9 | 0.010 |
Why?
|
| Oleic Acid | 1 | 1982 | 15 | 0.010 |
Why?
|
| Travel | 1 | 1983 | 116 | 0.010 |
Why?
|
| Defecation | 1 | 1982 | 29 | 0.010 |
Why?
|
| Triticum | 1 | 1982 | 34 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2002 | 40 | 0.010 |
Why?
|
| Kidney | 5 | 1980 | 1354 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2002 | 54 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 37 | 0.010 |
Why?
|
| Neutrophil Infiltration | 1 | 2002 | 64 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 152 | 0.010 |
Why?
|
| Sodium | 2 | 1982 | 295 | 0.010 |
Why?
|
| Energy Intake | 1 | 1985 | 492 | 0.010 |
Why?
|
| Calcium Carbonate | 1 | 1982 | 10 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1982 | 34 | 0.010 |
Why?
|
| Zea mays | 1 | 1982 | 43 | 0.010 |
Why?
|
| Lipolysis | 1 | 1982 | 82 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1983 | 152 | 0.010 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1982 | 7 | 0.010 |
Why?
|
| Milk, Human | 2 | 2001 | 301 | 0.010 |
Why?
|
| Louisiana | 1 | 2002 | 135 | 0.010 |
Why?
|
| Methods | 2 | 1978 | 149 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 240 | 0.010 |
Why?
|
| Dinucleotide Repeats | 1 | 2001 | 5 | 0.010 |
Why?
|
| Water | 1 | 1982 | 185 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1988 | 855 | 0.010 |
Why?
|
| Food Contamination | 1 | 2001 | 23 | 0.010 |
Why?
|
| Uremia | 1 | 1981 | 35 | 0.010 |
Why?
|
| Virus Activation | 1 | 1981 | 87 | 0.010 |
Why?
|
| Psychometrics | 1 | 2005 | 676 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 288 | 0.010 |
Why?
|
| Muramidase | 1 | 2000 | 93 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1982 | 298 | 0.010 |
Why?
|
| Protein Biosynthesis | 2 | 1983 | 665 | 0.010 |
Why?
|
| Macaca mulatta | 4 | 1984 | 492 | 0.010 |
Why?
|
| Trypsin Inhibitors | 1 | 1980 | 5 | 0.010 |
Why?
|
| Occupations | 1 | 2000 | 22 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2000 | 50 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1980 | 27 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2000 | 115 | 0.010 |
Why?
|
| Formamides | 1 | 1999 | 2 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1999 | 28 | 0.010 |
Why?
|
| Microspheres | 1 | 1979 | 71 | 0.010 |
Why?
|
| Glycine | 1 | 2000 | 167 | 0.010 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 1999 | 4 | 0.010 |
Why?
|
| Viruses, Unclassified | 1 | 1979 | 1 | 0.010 |
Why?
|
| Sheep Diseases | 1 | 1999 | 7 | 0.010 |
Why?
|
| Animal Husbandry | 1 | 1999 | 10 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1984 | 891 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1999 | 26 | 0.010 |
Why?
|
| Spouses | 1 | 2000 | 66 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2002 | 292 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2001 | 220 | 0.010 |
Why?
|
| Models, Biological | 1 | 1984 | 1461 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 1984 | 507 | 0.010 |
Why?
|
| Blood Donors | 1 | 1999 | 62 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 1979 | 29 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 537 | 0.010 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1998 | 12 | 0.010 |
Why?
|
| CA-19-9 Antigen | 1 | 1998 | 10 | 0.010 |
Why?
|
| Cell-Free System | 2 | 1992 | 106 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1998 | 15 | 0.010 |
Why?
|
| Genomic Library | 1 | 1998 | 39 | 0.010 |
Why?
|
| Glycosylation | 1 | 1998 | 119 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1981 | 387 | 0.010 |
Why?
|
| Software | 1 | 2003 | 686 | 0.010 |
Why?
|
| Dogs | 1 | 1999 | 770 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 670 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1997 | 75 | 0.010 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1982 | 549 | 0.010 |
Why?
|
| Pneumonia | 1 | 1981 | 326 | 0.010 |
Why?
|
| beta-Lactamases | 1 | 1999 | 192 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 1977 | 18 | 0.010 |
Why?
|
| Emaciation | 1 | 1976 | 2 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1997 | 154 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 1976 | 32 | 0.010 |
Why?
|
| Dehydration | 1 | 1976 | 39 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 1999 | 279 | 0.010 |
Why?
|
| Peritonitis | 1 | 1977 | 75 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1996 | 33 | 0.010 |
Why?
|
| Collagen Diseases | 1 | 1976 | 3 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 1996 | 12 | 0.010 |
Why?
|
| Epidermolysis Bullosa | 1 | 1976 | 18 | 0.010 |
Why?
|
| Hypochlorous Acid | 1 | 1996 | 5 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1997 | 105 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1977 | 103 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 1272 | 0.010 |
Why?
|
| Epidemiologic Factors | 1 | 1995 | 8 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 3 | 1982 | 218 | 0.010 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 1976 | 77 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1976 | 56 | 0.010 |
Why?
|
| Free Radicals | 1 | 1995 | 31 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 1996 | 138 | 0.010 |
Why?
|
| Alcoholics Anonymous | 1 | 1975 | 3 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1975 | 250 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1976 | 93 | 0.010 |
Why?
|
| Abscess | 1 | 1976 | 139 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1976 | 120 | 0.010 |
Why?
|
| Movement | 1 | 1976 | 171 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1976 | 202 | 0.010 |
Why?
|
| Venules | 1 | 1994 | 25 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 202 | 0.010 |
Why?
|
| Mumps virus | 1 | 1974 | 4 | 0.010 |
Why?
|
| Parotitis | 1 | 1974 | 5 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1974 | 65 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1974 | 39 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1975 | 141 | 0.010 |
Why?
|
| Phenmetrazine | 1 | 1973 | 1 | 0.010 |
Why?
|
| Cephalothin | 1 | 1973 | 6 | 0.010 |
Why?
|
| Postoperative Complications | 3 | 1981 | 3068 | 0.010 |
Why?
|
| Meningitis | 1 | 1974 | 98 | 0.010 |
Why?
|
| Methicillin | 1 | 1973 | 43 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1993 | 137 | 0.010 |
Why?
|
| Heroin Dependence | 1 | 1973 | 56 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 188 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1994 | 235 | 0.010 |
Why?
|
| Cell Communication | 1 | 1993 | 167 | 0.010 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1973 | 63 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 224 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1992 | 89 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1992 | 209 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1994 | 803 | 0.010 |
Why?
|
| Inclusion Bodies, Viral | 2 | 1982 | 11 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1991 | 43 | 0.010 |
Why?
|
| RNA Probes | 1 | 1990 | 30 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1973 | 244 | 0.010 |
Why?
|
| Cytoplasm | 2 | 1982 | 291 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1990 | 228 | 0.010 |
Why?
|
| Plasmids | 1 | 1990 | 514 | 0.010 |
Why?
|
| Morphogenesis | 2 | 1981 | 212 | 0.010 |
Why?
|
| Juxtaglomerular Apparatus | 1 | 1969 | 7 | 0.010 |
Why?
|
| Hyperaldosteronism | 1 | 1969 | 16 | 0.010 |
Why?
|
| Hypokalemia | 1 | 1969 | 41 | 0.000 |
Why?
|
| Cell Nucleus | 2 | 1982 | 677 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1991 | 768 | 0.000 |
Why?
|
| Staphylococcal Infections | 1 | 1973 | 558 | 0.000 |
Why?
|
| Repressor Proteins | 1 | 1991 | 820 | 0.000 |
Why?
|
| Immune Sera | 1 | 1986 | 95 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1986 | 167 | 0.000 |
Why?
|
| Avidin | 1 | 1985 | 18 | 0.000 |
Why?
|
| Biotin | 1 | 1985 | 45 | 0.000 |
Why?
|
| Injections, Subcutaneous | 1 | 1984 | 126 | 0.000 |
Why?
|
| Colloids | 1 | 1984 | 17 | 0.000 |
Why?
|
| Climate | 1 | 1984 | 20 | 0.000 |
Why?
|
| South America | 1 | 1984 | 38 | 0.000 |
Why?
|
| Population Density | 1 | 1984 | 34 | 0.000 |
Why?
|
| Inclusion Bodies | 1 | 1984 | 48 | 0.000 |
Why?
|
| Leukocytes | 1 | 1985 | 206 | 0.000 |
Why?
|
| Protein Sorting Signals | 1 | 1983 | 38 | 0.000 |
Why?
|
| Microsomes | 1 | 1983 | 56 | 0.000 |
Why?
|
| Peptide Biosynthesis | 1 | 1983 | 19 | 0.000 |
Why?
|
| Carbohydrate Sequence | 1 | 1982 | 17 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1983 | 73 | 0.000 |
Why?
|
| Forecasting | 1 | 1984 | 352 | 0.000 |
Why?
|
| Seasons | 1 | 1984 | 311 | 0.000 |
Why?
|
| Capsid Proteins | 1 | 1982 | 182 | 0.000 |
Why?
|
| Melena | 1 | 1981 | 5 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1982 | 187 | 0.000 |
Why?
|
| von Willebrand Diseases | 1 | 1982 | 51 | 0.000 |
Why?
|
| Carcinoma in Situ | 1 | 1981 | 71 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1980 | 97 | 0.000 |
Why?
|
| DEAE-Dextran | 1 | 1979 | 5 | 0.000 |
Why?
|
| Alkalies | 1 | 1979 | 24 | 0.000 |
Why?
|
| Amino Acids | 1 | 1982 | 663 | 0.000 |
Why?
|
| Chelating Agents | 1 | 1979 | 42 | 0.000 |
Why?
|
| Solvents | 1 | 1979 | 43 | 0.000 |
Why?
|
| Cholelithiasis | 1 | 1978 | 16 | 0.000 |
Why?
|
| Gallbladder | 1 | 1978 | 20 | 0.000 |
Why?
|
| Wounds, Stab | 1 | 1977 | 38 | 0.000 |
Why?
|
| Lysosomes | 1 | 1980 | 236 | 0.000 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1978 | 95 | 0.000 |
Why?
|
| Debridement | 1 | 1977 | 89 | 0.000 |
Why?
|
| Wounds, Gunshot | 1 | 1977 | 139 | 0.000 |
Why?
|
| Drainage | 1 | 1977 | 258 | 0.000 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1977 | 215 | 0.000 |
Why?
|
| Surgical Wound Infection | 1 | 1977 | 265 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1977 | 305 | 0.000 |
Why?
|
| Mitochondria | 1 | 1980 | 692 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1974 | 98 | 0.000 |
Why?
|
| Phosphorus | 1 | 1974 | 56 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1974 | 429 | 0.000 |
Why?
|
| Plasma Volume | 1 | 1969 | 15 | 0.000 |
Why?
|
| Blood Volume Determination | 1 | 1969 | 9 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1969 | 73 | 0.000 |
Why?
|
| Aldosterone | 1 | 1969 | 61 | 0.000 |
Why?
|
| Renin | 1 | 1969 | 94 | 0.000 |
Why?
|
| Hematocrit | 1 | 1969 | 111 | 0.000 |
Why?
|
| Kidney Glomerulus | 1 | 1969 | 78 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1969 | 122 | 0.000 |
Why?
|
| Posture | 1 | 1969 | 153 | 0.000 |
Why?
|
| Angiotensin II | 1 | 1969 | 163 | 0.000 |
Why?
|
| Body Weight | 1 | 1969 | 1005 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1969 | 1142 | 0.000 |
Why?
|
| Insulin | 1 | 1969 | 1210 | 0.000 |
Why?
|